{"gene":"ADAR","run_date":"2026-06-09T22:02:41","timeline":{"discoveries":[{"year":2015,"finding":"A-to-I editing of endogenous dsRNA by ADAR1 is the essential function required to prevent activation of the cytosolic dsRNA sensor MDA5. Editing-deficient knock-in mice (E861A) died at ~E13.5 with activated interferon and dsRNA-sensing pathways; embryonic death was rescued by concurrent deletion of MDA5. Genome-wide analysis identified clustered hyperediting within long dsRNA stem loops in 3' UTRs of endogenous transcripts as primary ADAR1 substrates.","method":"Editing-deficient knock-in mouse (E861A), genetic rescue by MDA5 deletion, genome-wide substrate mapping","journal":"Science","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vivo knock-in mutagenesis combined with genetic epistasis (MDA5 rescue) and genome-wide substrate identification, replicated across multiple labs","pmids":["26275108"],"is_preprint":false},{"year":2018,"finding":"ADAR1 prevents translational shutdown by inhibiting hyperactivation of PKR, a dsRNA sensor. In ADAR1 knockout human cells, endogenous Alu elements in pol II-transcribed mRNAs were the primary editing substrates. Both dsRNA binding and catalytic activities of ADAR1 were required to fully prevent endogenous RNA from activating PKR. ADAR1 knockout neuronal progenitor cells exhibited MDA5-dependent spontaneous interferon production, PKR activation, and cell death.","method":"ADAR1 knockout human cells, mechanistic dissection with catalytic and dsRNA-binding mutants, cell-type specific phenotyping","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — KO cells with multiple orthogonal functional validations (catalytic mutant, dsRNA-binding mutant, PKR activation assay, MDA5 dependence), single lab but multiple methods","pmids":["29395325"],"is_preprint":false},{"year":2014,"finding":"Adar1 embryonic lethality is rescued to live birth in Adar1;Mavs double mutants, demonstrating that the antiviral interferon induction response to cytoplasmic dsRNA drives the lethal phenotype. Restoring editing-active cytoplasmic ADAR1 dramatically reduced aberrant immune responses in Adar1 mutant MEFs. dsRNA oligonucleotides containing inosine-uracil base pairs reduced the aberrant innate immune response, consistent with inosine in cellular RNA inhibiting RLR interactions.","method":"Genetic rescue (double mutant mice), MEF transfection with inosine-containing dsRNA, reintroduction of editing-active ADAR1","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with double-mutant rescue and biochemical rescue in MEFs, replicated concept across multiple labs","pmids":["25456137"],"is_preprint":false},{"year":2022,"finding":"ADAR1 inhibits spontaneous activation of ZBP1 by preventing accumulation of endogenous Z-form dsRNAs (Z-RNAs). The Zα domain of ADAR1 promotes A-to-I editing of endogenous Alu elements to prevent dsRNA formation through pairing of inverted Alu repeats, which can otherwise activate ZBP1. ZBP1 activation in ADAR1-deficient cells elicits caspase-8-dependent apoptosis and MLKL-mediated necroptosis. ZBP1 contributes to embryonic lethality of Adar-knockout mice.","method":"Adar knockout mice, Adar;Mavs double mutants, Zα domain mutation, cell death pathway analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic models with defined domain mutations, three independent papers published simultaneously confirm the same mechanism","pmids":["35859175","35859177","35859176"],"is_preprint":false},{"year":2022,"finding":"The ZBD (Zα domain) point mutation of ADAR1 drives pathology through ZBP1 activation. Ablation of ZBP1 fully rescued overt pathology caused by ADAR1 Zα domain alteration. Loss of RIPK3 partially phenocopied ZBP1 ablation, while combined deletion of caspase-8 and RIPK3, or caspase-8 and MLKL, exacerbated pathogenic effects, indicating ZBP1-dependent signaling underlies the autoinflammatory pathology.","method":"Genetic epistasis in mice: Adar1 ZBD mutant crossed with ZBP1 KO, RIPK3 KO, caspase-8/RIPK3 double KO, caspase-8/MLKL double KO","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — rigorous in vivo epistasis with multiple genetic combinations, independently replicated by two other simultaneous Nature papers","pmids":["35859177"],"is_preprint":false},{"year":2022,"finding":"ADAR1 Zα domain prevents endogenous Z-RNA-dependent activation of ZBP1 that drives type I IFN responses. ZBP1 deficiency or mutation of its Zα domains reduced IFN-stimulated gene expression and prevented early postnatal lethality in Adar1mZα/- mice. ZBP1 promoted IFN activation independently of RIPK1, RIPK3, MLKL-mediated necroptosis and caspase-8-dependent apoptosis, suggesting a novel signaling mechanism. Adar1mZα/- mice showed upregulation and impaired editing of endogenous retroelement-derived complementary RNA reads as a likely Z-RNA source.","method":"Adar1mZα/- mouse model, ZBP1 deficiency rescue, Zα domain mutation of ZBP1, RNA sequencing","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo epistasis with domain-specific mutations, independently confirmed by two simultaneously published Nature papers","pmids":["35859176"],"is_preprint":false},{"year":2022,"finding":"ADAR1 prevents accumulation of endogenous Z-RNA elements enriched in 3' UTRs of interferon-stimulated mRNAs. Depletion or mutation of ADAR1 resulted in Z-RNA accumulation and activation of the Z-RNA sensor ZBP1, culminating in RIPK3-mediated necroptosis. ADAR1 interaction with ZBP1 Zα2 domain limits ZBP1 and RIPK3 interactions, suppressing PANoptosis.","method":"ADAR1 depletion, Z-RNA detection, ZBP1 activation assay, RIPK3 functional analysis, co-immunoprecipitation of ADAR1 with ZBP1","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (Z-RNA detection, Co-IP, genetic rescue), results confirmed across multiple simultaneous publications","pmids":["35614224","34686350"],"is_preprint":false},{"year":2021,"finding":"ADAR1 suppresses ZBP1-mediated PANoptosis by directly interacting with the Zα2 domain of ZBP1, limiting ZBP1-RIPK3 interactions. Combining interferons and nuclear export inhibitors activates ZBP1-dependent PANoptosis. Adar1fl/fl LysMcre mice are resistant to development of colorectal cancer and melanoma, but deletion of the ZBP1 Zα2 domain restores tumorigenesis.","method":"Co-immunoprecipitation, genetic mouse models (Adar1 conditional KO, ZBP1 Zα2 domain deletion), tumor models","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP demonstrating direct interaction, combined with in vivo epistasis in tumor models with domain-specific deletion","pmids":["34686350"],"is_preprint":false},{"year":2024,"finding":"ADAR1 dsRBD3 directly interacts with the PKR kinase domain on dsRNA to inhibit PKR activation. AlphaFold modeling predicted an inhibitory ADAR1 dsRBD3-PKR kinase domain interaction on dsRNA. Wild-type or editing-inactive human ADAR1 expressed in A549 cells inhibited activation of endogenous PKR. ADAR1 dsRNA binding is required but not sufficient for PKR inhibition; mutating the ADAR1 dsRBD3-PKR contact prevented co-immunoprecipitation, PKR inhibition, and co-localization. Adar Mavs Eifak2 (Pkr) triple mutant mice rescued all defects and showed long-term survival.","method":"Co-immunoprecipitation, editing-inactive ADAR1 mutant, dsRBD3-PKR contact mutant, AlphaFold structural modeling, triple-mutant mouse model","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct interaction mapped by mutagenesis with structural model, editing-inactive mutant shows editing-independence, in vivo genetic rescue confirms pathway","pmids":["39146181"],"is_preprint":false},{"year":2025,"finding":"PACT cooperates with ADAR1 to suppress PKR activation by self-dsRNAs. Simultaneous deletion of PACT and ADAR1 results in synthetic lethality, fully rescued in PKR-deficient cells. PACT-deficient cells hyperactivate PKR in response to RNA viruses.","method":"FACS-based genome-wide CRISPR-Cas9 knockout screen (CRISPR-Translate), double KO synthetic lethality, PKR KO rescue","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide screen with genetic epistasis (synthetic lethality rescued by PKR KO), orthogonal functional validation","pmids":["40185749"],"is_preprint":false},{"year":2021,"finding":"ADAR1 p150 and p110 have distinct editing preferences determined primarily by their intracellular localization, not by the Zα domain. More than half of A-to-I edit sites are selectively edited by p150, while the other half are edited by either p150 or p110. p110 is co-expressed with p150 from the canonical p150-encoding mRNA due to leaky ribosome scanning downstream of the p150 start codon.","method":"ADAR1 KO cells reconstituted with modified isoform-selective constructs, RNA editing analysis, synonymous mutation to prevent leaky scanning","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 / Strong — isoform-selective reconstitution in KO cells with genome-wide editing analysis and mechanistic follow-up on translation initiation","pmids":["33723056"],"is_preprint":false},{"year":2023,"finding":"Isoform-specific editing by ADAR1 is primarily directed by intracellular localization (cytoplasmic p150 vs. nuclear p110), with ZBDα only minimally contributing to p150-specific editing preferences. ADAR1p110 preferentially binds and edits intronic sequences while ADAR1p150 preferentially binds and edits 3' UTRs.","method":"Transfection of ADAR1 isoforms into ADAR-less mouse cells, localization mutants, Zα domain mutants, RIP-seq","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — isoform and localization mutant analysis with RIP-seq, complemented by genome-wide editing analysis","pmids":["37026479"],"is_preprint":false},{"year":2020,"finding":"ADAR1 is downregulated by autophagic degradation during cellular senescence, driving senescence through p16INK4a upregulation in an RNA-editing-independent manner. Mechanistically, ADAR1 promotes SIRT1 expression by affecting its RNA stability through HuR. SIRT1 antagonizes translation of mRNA encoding p16INK4a. ADAR1 downregulation is sufficient to drive senescence both in vitro and in vivo.","method":"Autophagic degradation assay, ADAR1 KD/KO in vitro and in vivo, editing-inactive mutant, HuR interaction, SIRT1/p16INK4a pathway analysis","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — editing-inactive mutant establishes editing-independence, pathway dissected with multiple orthogonal methods in vitro and in vivo","pmids":["35851616"],"is_preprint":false},{"year":2018,"finding":"ADAR1 controls ITGB3 expression and melanoma cell invasiveness via editing-independent mechanisms: ADAR1 regulates miR-22 expression through FOXD1 transcription factor, and miR-22 directly regulates ITGB3 expression. ADAR1 also regulates ITGB3 at the transcriptional level via PAX6. Re-expression of either wild-type or catalytically inactive ADAR1 reversed the enhanced invasion caused by ADAR1 silencing.","method":"ADAR1 silencing/re-expression, catalytically inactive ADAR1 mutant, ITGB3 antibody blockade, miR-22/FOXD1/PAX6 pathway analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — catalytically inactive mutant establishes editing-independence, multiple downstream pathway components validated","pmids":["29855470"],"is_preprint":false},{"year":2023,"finding":"ADAR1 interacts with TOPBP1 and facilitates TOPBP1 loading on perturbed replication forks by enhancing TOPBP1 association with RAD9 of the 9-1-1 complex, thereby promoting ATR activation. When replication is inhibited, DNA-RNA hybrids (R-loops) compete with TOPBP1 for ADAR1 binding, causing ADAR1 translocation from damaged forks to R-loop regions where it recruits RNA helicases DHX9 and DDX21 to unwind R-loops. ADAR1's dsRNA-binding domains are required for this function.","method":"Co-immunoprecipitation, proximity ligation, ADAR1 dsRBD mutants, R-loop detection (S9.6 antibody), ATR activation assays, helicase interaction studies","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple Co-IPs with defined domain mutants, mechanistic pathway dissected with orthogonal methods","pmids":["37831098"],"is_preprint":false},{"year":2016,"finding":"ADAR1 suppresses LINE-1 (L1) retrotransposition independently of its editing activity. ADAR1 was found in the basal L1 RNP complex. By dual-tag affinity purification during HIV-1 expression, 14 non-ribosomal ADAR1-interacting proteins were identified, many associated with LINE-1 ribonucleoparticles.","method":"Dual-tag affinity purification, mass spectrometry, cell-culture retrotransposition assays (editing-inactive ADAR1 mutant)","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — editing-independent mechanism established with editing-inactive mutant and direct binding to L1 RNP shown, single lab","pmids":["27658966"],"is_preprint":false},{"year":2023,"finding":"ADAR1 interacts with Drosha to promote its degradation, attenuating Drosha-DGCR8 interaction and consequently inhibiting pri- to pre-microRNA processing of microRNAs targeting IKKβ. This results in increased IKKβ expression and enhanced NF-κB signaling in macrophages, promoting vascular inflammation. This function is editing-independent.","method":"Co-immunoprecipitation (ADAR1-Drosha interaction), macrophage-specific ADAR1 KO, aortic transplantation, human AAA specimens, humanized AAA model","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP demonstrating ADAR1-Drosha interaction, validated in vivo in multiple mouse models and human tissue","pmids":["36688311"],"is_preprint":false},{"year":2013,"finding":"ADAR1 forms a complex with Dicer via direct protein-protein interaction. ADAR1 in the Dicer complex promotes pre-miRNA cleavage by Dicer and facilitates miRNA loading onto RISC, stimulating miRNA processing and RNAi. ADAR1 differentiates its functions by forming either ADAR1 homodimers or Dicer-ADAR1 heterodimers. miRNA expression is globally inhibited in ADAR1-null mouse embryos.","method":"Co-immunoprecipitation, in vitro Dicer cleavage assay, ADAR1-null mouse embryo analysis","journal":"RNA biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus functional assay plus in vivo phenotype, single lab","pmids":["23949595"],"is_preprint":false},{"year":2020,"finding":"ILF3, ILF2, STRBP, and ZFR (DZF-domain-containing proteins) interact with ADAR1 and ADAR2 and modulate RNA editing levels. ILF3 functions as a broadly influential negative regulator of editing. These were identified as trans regulators by BioID proximity labeling followed by mass spectrometry.","method":"BioID proximity labeling, mass spectrometry, ENCODE data validation, siRNA knockdown of identified interactors with editing level measurement","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — BioID plus functional validation of editing regulation, single lab","pmids":["32433965"],"is_preprint":false},{"year":2024,"finding":"ADAR1 nuclear (p110) and cytoplasmic (p150) isoforms have distinct protein interactomes. Nuclear proteins are stable interactors with both isoforms. ADAR1p110 associates with nuclear components while ADAR1p150 associates with cytoplasmic cellular condensates. dsRNA binding is important for ADAR1 interactions. IFN treatment results in novel interactions, and during IFN response with poly(I:C), ADAR1p150 proximal network associates with antiviral stress granule components.","method":"Co-IP of endogenous ADAR1, Strep-tag Co-IP, BioID with individual isoforms, RNase A digestion, dsRNA-binding mutant","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — three orthogonal methods (endogenous Co-IP, tag Co-IP, BioID) with dsRNA-binding mutant controls to distinguish direct vs. RNA-mediated interactions","pmids":["39673305"],"is_preprint":false},{"year":2024,"finding":"ADAR1 dsRBD3 forms a stable homodimer, and dimerization disruption via interface mutation does not abrogate editing activity but intricately affects editing efficiency at selected sites, indicating dimerization regulates site specificity rather than global catalytic activity.","method":"Crystal structure of ADAR1 dsRBD3, interface mutagenesis, in vitro editing assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure combined with mutagenesis and in vitro editing assay, single lab","pmids":["39572551"],"is_preprint":false},{"year":2018,"finding":"The ADAR1 deaminase domain (hADAR1d) has different substrate selectivity from ADAR2. A chimeric protein bearing an RNA-binding loop from hADAR2d grafted onto hADAR1d showed ADAR2-like selectivity, demonstrating that substrate selectivity originates primarily from the deaminase domain RNA-binding loop. High-throughput mutagenesis (Sat-FACS-Seq) identified essential amino acids in an RNA-binding loop of hADAR1d.","method":"In vitro deamination assays, chimeric domain swap, Sat-FACS-Seq high-throughput mutagenesis","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with domain swaps and systematic mutagenesis, single lab but multiple orthogonal methods","pmids":["29457714"],"is_preprint":false},{"year":2022,"finding":"ADAR1-dependent RNA editing of the 3'-UTR of GM2A (ganglioside catabolism activator) is critical for GBM stem cell self-renewal and stemness. ADAR1 inactivation or JAK/STAT pathway inhibition via TYK2 inhibition impaired GSC self-renewal. ADAR1 and global RNA editomes are elevated in GSCs compared with normal neural stem cells.","method":"ADAR1 inactivation, TYK2 inhibition, functional assays (self-renewal, stemness), 3'-UTR editing analysis of GM2A","journal":"Journal of Clinical Investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional KO with specific editing substrate identified (GM2A 3'-UTR), upstream pathway (JAK/STAT-TYK2) tested, single lab","pmids":["35133980"],"is_preprint":false},{"year":2021,"finding":"ADAR1 editing-dependent RNA modification of CDK13 coding sequence (c.308A>G) promotes cancer cell hallmarks in thyroid cancer. This editing event increases nucleolar abundance of CDK13 protein and contributes to global changes in splicing produced by ADAR1 deregulation.","method":"Whole transcriptome sequencing, ADAR1 silencing, cell viability/proliferation/invasion assays, subnuclear localization analysis","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — specific editing site identified with functional consequences measured, single lab with multiple cell-based assays","pmids":["34496885"],"is_preprint":false},{"year":2022,"finding":"ADAR1-dependent editing of miR-3144-3p at position 3 in the seed region redirects its targeting: edited miR-3144-3p upregulates MSI2 (by no longer suppressing it) and suppresses SLC38A4, contributing to hepatocellular carcinogenesis.","method":"RNA editing site identification, miRNA mimic transfection, target validation by luciferase/Western, ADAR1 siRNA/KO, mouse tumor model","journal":"Experimental & Molecular Medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — specific editing site mechanistically linked to miRNA retargeting with in vivo validation, single lab","pmids":["36599932"],"is_preprint":false},{"year":2020,"finding":"ADAR1 editing of dsRNA prevents MDA5 sensing and sequestration of dsRNAs encoding membrane proteins that promote ER homeostasis. Absence of ADAR1-dependent editing induces aberrant innate immune responses through MDA5, unleashing ER stress and hindering epithelial fate acquisition during MET and iPSC reprogramming. The PERK-dependent unfolded protein response pathway is activated downstream.","method":"ADAR1 KO and chemical inhibition during reprogramming, MDA5 KO rescue, ER stress markers, PERK pathway analysis","journal":"Cell stem cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic rescue with MDA5 KO demonstrates epistasis, mechanistic pathway connected, single lab","pmids":["32396862"],"is_preprint":false},{"year":2023,"finding":"ADAR1 interacts with DHX9 in ovarian cancer cells to regulate R-loop complex formation. Loss of ADAR1 causes R-loop abnormal accumulation, contributing to single-strand DNA breaks and ATR pathway activation. A-to-I editing of nascent RNA by ADAR1 suppresses R-loop formation during co-transcriptional processes.","method":"Co-immunoprecipitation (ADAR1-DHX9), R-loop detection, ATR activation assays, ADAR1 silencing, cell cycle analysis","journal":"Journal of Cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus functional R-loop and ATR assays, single lab","pmids":["35711824"],"is_preprint":false},{"year":2022,"finding":"ADAR1-mediated A-to-I editing globally alters RNA secondary structure in a context-dependent manner. ADAR1 silencing results in a lower global double-stranded to single-stranded RNA ratio, meaning editing can stabilize a large subset of imperfect RNA duplexes (inverted Alus in UTRs). The destabilized duplexes are predominantly cytoplasmic and show higher ribosomal occupancy.","method":"Parallel analysis of RNA structure sequencing (PARS-seq) in ADAR1-deficient cells","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide structural analysis method (PARS-seq) in KD cells, single lab","pmids":["29129909"],"is_preprint":false},{"year":2014,"finding":"ADAR1 p150 is an IFN-inducible isoform found in both cytoplasm and nucleus, while ADAR1 p110 is constitutively expressed and nuclear. ADAR1-dependent A-to-I editing can alter RNA structure stability, mRNA coding, and splicing; inosine is decoded as guanosine by ribosomes and polymerases.","method":"Isoform characterization via alternative promoter analysis, fractionation, biochemical assays","journal":"Journal of Interferon & Cytokine Research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical fractionation and isoform characterization, foundational mechanistic description replicated across many labs","pmids":["24905200"],"is_preprint":false},{"year":2024,"finding":"Loss of ADAR1 in breast cancer cells induces ferroptosis via a miR-335-5p/Sp1/GPX4 pathway. ADAR1 controls miR-335-5p levels; reduced ADAR1 increases miR-335-5p which targets Sp1, a transcription factor for GPX4, leading to decreased GPX4 and ferroptosis. This function is independent of ADAR1's RNA editing activity.","method":"CRISPR-Cas9 KO and plasmid overexpression of ADAR1, miR-335-5p measurements, ROS/MDA/GSH/Fe2+ assays, GPX4 protein levels","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR KO with pathway validation and editing-independent conclusion, single lab","pmids":["38866351"],"is_preprint":false},{"year":2022,"finding":"ADAR1 prevents autoinflammatory myocarditis in cardiomyocytes via IRF7 as the main mediator. Enzymatic RNA editing activity prevents IRF7-mediated autoinflammatory reactions triggered by endogenous non-edited RNAs via MDA5; additionally ADAR1 serves editing-independent roles required for long-term cardiac function.","method":"Cardiomyocyte-specific Adar1 KO mice, MDA5 (Ifih1) KO rescue, Irf7 KO rescue, catalytically inactive ADAR1 in Ifih1 mutant background","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple epistasis crosses with catalytically inactive mutant to separate editing-dependent from -independent roles, in vivo cardiac phenotype","pmids":["36000401"],"is_preprint":false},{"year":2020,"finding":"ADAR1 establishes a negative-feedback loop restricting the viral mimicry response to epigenetic therapy. Intronic and intergenic SINE elements (inverted-repeat Alus) are the major source of drug-induced immunogenic dsRNA. ADAR1 targets and destabilizes inverted-repeat Alu dsRNA, preventing MDA5 receptor activation. Depletion of ADAR1 in patient-derived cancer cells potentiates epigenetic therapy efficacy.","method":"Epigenetic drug treatment, ADAR1 depletion, dsRNA immunofluorescence, MDA5 activation assays, tumor growth assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — identified specific RNA species (inverted-repeat Alus) as ADAR1 substrates in drug context, functional rescue and patient-derived cells","pmids":["33087935"],"is_preprint":false},{"year":2022,"finding":"ADAR1 p150 editing activity prevents MDA5-mediated sensing in cardiomyocytes through its RNA editing activity, while ADAR1 p110 does not contribute to this function. The Zα domain-Z-RNA interaction is required for p150 editing specificity at certain sites critical for preventing MDA5 activation.","method":"Isoform-specific mouse mutants, MDA5 (Ifih1) KO rescue, Zα domain point mutation (W197A)","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific mouse models with Zα domain mutation, single lab, confirmed by other groups using similar models","pmids":["34768866"],"is_preprint":false},{"year":2023,"finding":"ADAR1-mediated editing of miR-376b-3p in the seed region redirects its target mRNAs to include 4-aminobutyrate aminotransferase (ABAT), the enzyme for GABA catabolism. Edited miR-376b-3p expression increases intracellular GABA levels and cell surface GABA type A receptors. ADAR2 negatively regulates miR-376b-3p maturation in an editing-independent manner.","method":"ADAR1/ADAR2 editing analysis of miRNA precursors and mature forms, miRNA target prediction and validation, GABA measurement, GABA-A receptor surface expression","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — specific editing-dependent retargeting validated functionally, editing-independent ADAR2 effect also shown, single lab","pmids":["35124003"],"is_preprint":false},{"year":2020,"finding":"ADAR1 requires RNA editing activity to regulate early thymocyte development in part through MDA5 (concurrent MDA5 deletion ameliorated apoptosis but did not restore impaired transition and TCR expression), indicating RNA-editing-dependent and -independent functions of ADAR1 synergistically regulate early thymocyte development.","method":"Early thymocyte-specific ADAR1 conditional KO, MDA5 KO rescue, forced TCR expression rescue experiments","journal":"Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with multiple rescue experiments distinguishing editing-dependent from -independent roles, single lab","pmids":["32169840"],"is_preprint":false}],"current_model":"ADAR1 is an RNA editing enzyme that converts adenosine to inosine (A-to-I) in double-stranded RNA substrates via its deaminase domain, with two isoforms (IFN-inducible cytoplasmic p150 and constitutive nuclear p110) that have distinct substrate preferences determined by their localization and Zα domain; its primary essential function is to mark endogenous dsRNAs (especially inverted Alu repeat-containing transcripts) with inosine to prevent their recognition as 'nonself' by cytosolic sensors MDA5, PKR, and ZBP1—with editing-dependent inhibition of MDA5 preventing interferon induction, direct dsRBD3-mediated inhibition of PKR kinase domain preventing translational shutdown, and Zα domain-mediated editing of Z-RNA substrates preventing ZBP1-driven PANoptosis/necroptosis—while also performing editing-independent functions including direct interaction with Dicer to stimulate miRNA processing, interaction with Drosha to promote its degradation (regulating NF-κB via microRNA processing), interaction with TOPBP1/RAD9 to promote ATR activation and R-loop clearance via DHX9/DDX21 recruitment, and autophagic degradation-mediated regulation of senescence through a SIRT1/p16INK4a axis."},"narrative":{"mechanistic_narrative":"ADAR1 is an adenosine-to-inosine RNA editing enzyme whose essential physiological role is to mark endogenous double-stranded RNAs—especially long stem-loops formed by inverted Alu/SINE repeats in 3' UTRs and intronic regions—with inosine so they are not misread as 'nonself' by cytosolic dsRNA sensors [PMID:26275108, PMID:29395325, PMID:33087935]. Editing-dead knock-in mice die in utero with runaway interferon signaling, and this lethality is rescued by deleting the dsRNA sensor MDA5 or the downstream adaptor MAVS, establishing that A-to-I editing destabilizes immunogenic duplexes and prevents MDA5/RLR activation [PMID:26275108, PMID:25456137, PMID:36000401]. Beyond MDA5, ADAR1 restrains two additional sensors: its dsRBD3 directly contacts the PKR kinase domain on dsRNA to block PKR-driven translational shutdown (an interaction requiring dsRNA binding but independent of catalysis, with PACT acting as a cooperating suppressor) [PMID:39146181, PMID:40185749], and its Zα domain promotes editing of Z-form RNAs while directly binding the ZBP1 Zα2 domain to prevent ZBP1-driven necroptosis, apoptosis, and PANoptosis [PMID:35859175, PMID:35859177, PMID:35859176, PMID:35614224, PMID:34686350]. Two isoforms—the IFN-inducible, partly cytoplasmic p150 and the constitutive nuclear p110—arise from leaky ribosome scanning of a shared mRNA, and their distinct editing site preferences (p150 favoring 3' UTRs, p110 favoring introns) are dictated chiefly by subcellular localization rather than the Zα domain [PMID:33723056, PMID:37026479, PMID:24905200]. Substrate selectivity is encoded in an RNA-binding loop of the deaminase domain, and dsRBD3 homodimerization tunes site-specific editing efficiency [PMID:39572551, PMID:29457714]. ADAR1 also executes editing-independent functions: it stimulates Dicer-dependent pre-miRNA processing and RISC loading, promotes Drosha degradation to control NF-κB-linked microRNA biogenesis, and facilitates TOPBP1 loading and DHX9/DDX21-mediated R-loop resolution to support ATR activation at perturbed replication forks [PMID:36688311, PMID:23949595, PMID:37831098, PMID:35711824]. Through these activities ADAR1 governs interferon homeostasis, cell-death programs, miRNA biology, and genome stability, and its dysregulation is linked to senescence via a SIRT1/p16INK4a axis and to tumor cell fitness in multiple cancers [PMID:35851616, PMID:35133980, PMID:33087935].","teleology":[{"year":2014,"claim":"Established that the lethal consequence of ADAR1 loss is driven by an aberrant antiviral interferon response to cytoplasmic dsRNA, and that inosine in cellular RNA directly dampens RLR-type sensing.","evidence":"Adar1;Mavs double-mutant mice, MEF reconstitution with editing-active ADAR1, and transfection of inosine-containing dsRNA","pmids":["25456137"],"confidence":"High","gaps":["Did not identify which specific sensor downstream of MAVS is engaged","Endogenous substrate identity not mapped"]},{"year":2014,"claim":"Defined the two ADAR1 isoforms (IFN-inducible p150, constitutive nuclear p110) and the molecular consequences of inosine, framing editing as a modifier of RNA structure, coding, and splicing.","evidence":"Alternative promoter analysis, subcellular fractionation, biochemical isoform characterization","pmids":["24905200"],"confidence":"Medium","gaps":["Did not resolve isoform-specific substrate preferences","Did not link isoforms to specific sensor pathways"]},{"year":2015,"claim":"Pinpointed editing of endogenous long-stem dsRNA as the single essential ADAR1 function preventing MDA5 activation, by showing MDA5 deletion rescues editing-dead mice.","evidence":"Editing-deficient E861A knock-in mice, genetic rescue by MDA5 deletion, genome-wide substrate mapping","pmids":["26275108"],"confidence":"High","gaps":["Did not address non-MDA5 sensors","Editing-independent roles not examined"]},{"year":2016,"claim":"Revealed an editing-independent role in suppressing LINE-1 retrotransposition and provided a first interactome anchored in L1 ribonucleoprotein complexes.","evidence":"Dual-tag affinity purification/MS, retrotransposition assays with editing-inactive ADAR1","pmids":["27658966"],"confidence":"Medium","gaps":["Mechanism of L1 suppression not defined","Single lab, no in vivo confirmation"]},{"year":2018,"claim":"Demonstrated that ADAR1 prevents PKR-driven translational shutdown, requiring both dsRNA binding and catalysis, and that Alu elements in pol II transcripts are the principal substrates.","evidence":"ADAR1 KO human cells with catalytic and dsRNA-binding mutants, PKR activation assays, neuronal progenitor phenotyping","pmids":["29395325"],"confidence":"High","gaps":["Did not resolve whether PKR inhibition is direct or substrate-mediated","Cell-type dependence of phenotypes incompletely explained"]},{"year":2018,"claim":"Localized substrate selectivity to an RNA-binding loop within the deaminase domain, distinguishing ADAR1 from ADAR2 specificity.","evidence":"In vitro deamination, ADAR1d/ADAR2d chimeric domain swap, Sat-FACS-Seq mutagenesis","pmids":["29457714"],"confidence":"High","gaps":["Did not address how full-length context or dsRBDs modulate selectivity in cells"]},{"year":2018,"claim":"Showed editing-independent control of cell invasiveness through transcriptional and miRNA-mediated regulation of ITGB3 in melanoma.","evidence":"ADAR1 silencing/re-expression with catalytically inactive mutant, miR-22/FOXD1/PAX6 pathway analysis, ITGB3 blockade","pmids":["29855470"],"confidence":"High","gaps":["How ADAR1 regulates FOXD1/PAX6 mechanistically not defined"]},{"year":2020,"claim":"Connected ADAR1 to genome-wide RNA structure, showing editing can stabilize a large subset of cytoplasmic imperfect duplexes that influence ribosome occupancy.","evidence":"PARS-seq in ADAR1-deficient cells","pmids":["29129909"],"confidence":"Medium","gaps":["Correlational structure changes not tied to specific functional outcomes","Single lab"]},{"year":2020,"claim":"Established ADAR1 as a brake on therapy-induced viral mimicry, identifying inverted-repeat Alu dsRNA as the drug-induced immunogenic species it destabilizes.","evidence":"Epigenetic drug treatment, ADAR1 depletion, dsRNA imaging, MDA5 activation and tumor assays in patient-derived cells","pmids":["33087935"],"confidence":"High","gaps":["Did not establish whether p150 or p110 mediates the negative feedback"]},{"year":2020,"claim":"Linked ADAR1 editing to cell-fate programs by showing MDA5-driven innate immunity and ER stress block epithelial reprogramming when editing is lost.","evidence":"ADAR1 KO/inhibition during reprogramming, MDA5 KO rescue, PERK/UPR markers","pmids":["32396862"],"confidence":"Medium","gaps":["Identity of sequestered ER-protein-encoding dsRNAs not fully resolved","Single lab"]},{"year":2020,"claim":"Showed both editing-dependent (MDA5-linked) and editing-independent ADAR1 functions cooperate in early thymocyte development.","evidence":"Thymocyte-specific Adar1 KO, MDA5 KO rescue, forced TCR expression rescue","pmids":["32169840"],"confidence":"Medium","gaps":["Editing-independent function molecularly undefined","Single lab"]},{"year":2020,"claim":"Identified DZF-domain proteins, especially ILF3, as trans-acting regulators that modulate ADAR-mediated editing levels.","evidence":"BioID proximity labeling/MS, ENCODE validation, siRNA knockdown with editing readouts","pmids":["32433965"],"confidence":"Medium","gaps":["Mechanism by which ILF3 negatively regulates editing not defined","Single lab"]},{"year":2021,"claim":"Showed isoform editing preferences are set primarily by localization rather than the Zα domain, and that p110 co-arises from leaky scanning of the p150 mRNA.","evidence":"Isoform-selective reconstitution in ADAR1 KO cells, synonymous mutation to block leaky scanning, genome-wide editing analysis","pmids":["33723056"],"confidence":"High","gaps":["Did not quantify functional consequences of p110 from leaky scanning in vivo"]},{"year":2021,"claim":"Demonstrated a direct ADAR1–ZBP1 Zα2 interaction that limits ZBP1-RIPK3 engagement and suppresses PANoptosis, with tumor-relevant consequences.","evidence":"Co-IP, Adar1 conditional KO and ZBP1 Zα2 deletion mice, colorectal/melanoma tumor models","pmids":["34686350"],"confidence":"High","gaps":["Relative contribution of editing vs direct binding to ZBP1 control not fully separated"]},{"year":2021,"claim":"Provided an editing-dependent cancer mechanism via CDK13 coding-site editing that alters its nucleolar abundance and global splicing in thyroid cancer.","evidence":"Whole-transcriptome sequencing, ADAR1 silencing, proliferation/invasion assays, subnuclear localization","pmids":["34496885"],"confidence":"Medium","gaps":["Causal link between CDK13 editing and splicing changes not fully isolated","Single lab"]},{"year":2022,"claim":"Established the Zα domain–ZBP1 axis as the third sensor pathway restrained by ADAR1, with editing of Z-RNAs from inverted Alus/retroelements preventing ZBP1-driven necroptosis and apoptosis in vivo.","evidence":"Adar knockout and Zα-mutant mice, ZBP1/RIPK3/caspase-8/MLKL epistasis crosses, Z-RNA detection","pmids":["35859175","35859177","35859176","35614224","34686350"],"confidence":"High","gaps":["Exact Z-RNA structural features sensed not fully defined","ZBP1 IFN-induction mechanism reported as RIPK-independent but not molecularly resolved"]},{"year":2022,"claim":"Distinguished editing-dependent (MDA5/IRF7) from editing-independent ADAR1 roles in cardiomyocyte homeostasis using catalytically inactive mutants in vivo.","evidence":"Cardiomyocyte-specific Adar1 KO, Ifih1 and Irf7 KO rescues, catalytically inactive ADAR1 in Ifih1-null background","pmids":["36000401"],"confidence":"High","gaps":["Molecular identity of the editing-independent cardiac function undefined"]},{"year":2022,"claim":"Showed editing-independent downregulation of ADAR1 during senescence drives p16INK4a via a SIRT1/HuR axis.","evidence":"Autophagic degradation assays, ADAR1 KD/KO in vitro and in vivo, editing-inactive mutant, HuR/SIRT1/p16INK4a analysis","pmids":["35851616"],"confidence":"High","gaps":["How HuR-ADAR1 stabilizes SIRT1 mRNA mechanistically not detailed"]},{"year":2022,"claim":"Demonstrated an editing-dependent oncogenic dependency in glioblastoma stem cells through GM2A 3'-UTR editing downstream of JAK/STAT-TYK2.","evidence":"ADAR1 inactivation, TYK2 inhibition, self-renewal assays, GM2A 3'-UTR editing analysis","pmids":["35133980"],"confidence":"Medium","gaps":["Mechanism by which GM2A editing supports stemness not resolved","Single lab"]},{"year":2022,"claim":"Assigned the p150 isoform, via Zα-Z-RNA-guided editing specificity, as the responsible isoform preventing MDA5 activation in cardiomyocytes.","evidence":"Isoform-specific mouse mutants, Ifih1 KO rescue, Zα W197A point mutation","pmids":["34768866"],"confidence":"Medium","gaps":["Why p110 cannot substitute not fully explained","Single lab"]},{"year":2022,"claim":"Provided an editing-dependent miRNA-retargeting mechanism in hepatocellular carcinoma via miR-3144-3p seed editing.","evidence":"Editing site identification, miRNA mimic transfection, MSI2/SLC38A4 target validation, mouse tumor model","pmids":["36599932"],"confidence":"Medium","gaps":["Contribution relative to ADAR1's immune functions in HCC not assessed","Single lab"]},{"year":2023,"claim":"Refined isoform substrate preferences, showing localization (cytoplasmic p150 vs nuclear p110) drives 3'UTR vs intronic editing with only minor Zα contribution.","evidence":"ADAR1 isoform transfection into ADAR-less cells, localization and Zα mutants, RIP-seq","pmids":["37026479"],"confidence":"High","gaps":["Functional consequences of intronic p110 editing not detailed"]},{"year":2023,"claim":"Revealed an editing-independent genome-stability role: ADAR1 promotes TOPBP1 loading and ATR activation at stalled forks and is redeployed to clear R-loops via DHX9/DDX21.","evidence":"Co-IP, proximity ligation, dsRBD mutants, S9.6 R-loop detection, ATR activation assays","pmids":["37831098"],"confidence":"High","gaps":["How R-loops outcompete TOPBP1 for ADAR1 binding not structurally defined"]},{"year":2023,"claim":"Independently linked ADAR1-DHX9 interaction to R-loop suppression and ATR activation in cancer cells.","evidence":"Co-IP, R-loop detection, ATR assays, ADAR1 silencing, cell-cycle analysis in ovarian cancer cells","pmids":["35711824"],"confidence":"Medium","gaps":["Relative roles of editing vs binding in R-loop control not separated","Single lab"]},{"year":2023,"claim":"Established editing-independent control of Drosha stability linking ADAR1 to NF-κB-driven vascular inflammation.","evidence":"Co-IP of ADAR1-Drosha, macrophage-specific KO, aortic transplant, human AAA specimens, humanized model","pmids":["36688311"],"confidence":"High","gaps":["Mechanism of ADAR1-induced Drosha degradation not defined"]},{"year":2023,"claim":"Showed editing-dependent miR-376b-3p seed retargeting alters GABA metabolism via ABAT.","evidence":"Editing analysis of miRNA precursors/mature forms, target validation, GABA and GABA-A receptor measurements","pmids":["35124003"],"confidence":"Medium","gaps":["Physiological context of GABA-pathway regulation not established","Single lab"]},{"year":2024,"claim":"Resolved the direct, editing-independent mechanism of PKR inhibition: ADAR1 dsRBD3 contacts the PKR kinase domain on dsRNA, validated by structure-guided contact mutagenesis and triple-mutant rescue in vivo.","evidence":"Co-IP, editing-inactive and dsRBD3-PKR contact mutants, AlphaFold modeling, Adar;Mavs;Eifak2 triple-mutant mice","pmids":["39146181"],"confidence":"High","gaps":["Stoichiometry and structural detail of the inhibitory complex not crystallographically determined"]},{"year":2024,"claim":"Mapped distinct interactomes for nuclear p110 and cytoplasmic p150, showing dsRNA dependence and IFN-induced recruitment of p150 to antiviral stress granules.","evidence":"Endogenous and Strep-tag Co-IP, isoform-specific BioID, RNase A digestion, dsRNA-binding mutant","pmids":["39673305"],"confidence":"High","gaps":["Functional consequences of most isoform-specific partners not tested"]},{"year":2024,"claim":"Provided structural insight that dsRBD3 homodimerization tunes site-specific editing efficiency rather than global catalysis.","evidence":"Crystal structure of dsRBD3, interface mutagenesis, in vitro editing assays","pmids":["39572551"],"confidence":"High","gaps":["In vivo relevance of dimerization-dependent site selectivity not demonstrated"]},{"year":2024,"claim":"Showed editing-independent suppression of ferroptosis via a miR-335-5p/Sp1/GPX4 axis in breast cancer.","evidence":"CRISPR KO and overexpression, miR-335-5p measurements, ROS/MDA/GSH/Fe2+ assays, GPX4 levels","pmids":["38866351"],"confidence":"Medium","gaps":["How ADAR1 controls miR-335-5p editing-independently not defined","Single lab"]},{"year":2025,"claim":"Identified PACT as a cooperating suppressor of PKR alongside ADAR1, with synthetic lethality of combined loss rescued by PKR deletion.","evidence":"Genome-wide CRISPR-Cas9 FACS screen, ADAR1/PACT double KO, PKR KO rescue","pmids":["40185749"],"confidence":"High","gaps":["Whether PACT and ADAR1 act on the same dsRNAs or independently not resolved"]},{"year":null,"claim":"How ADAR1's many editing-independent activities (PKR/ZBP1 binding, Dicer/Drosha control, TOPBP1/R-loop functions, senescence and ferroptosis axes) are coordinated, isoform-partitioned, and prioritized within a cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model integrating editing-dependent and editing-independent roles","Structural basis of most direct protein interactions undefined","In vivo relevance of cancer-specific editing substrates versus immune functions unclear"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,1,21,28]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[1,8,14,19]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[8,16]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[8,7,6]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[11,19,28]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[11,19,28]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[23]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,2,3,30]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[0,27,17]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[3,4,6,7,29]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[14,26]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[12,25]}],"complexes":["Dicer-ADAR1 complex","LINE-1 RNP"],"partners":["MDA5","PKR","ZBP1","TOPBP1","DHX9","DROSHA","DICER","PACT"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P55265","full_name":"Double-stranded RNA-specific adenosine deaminase","aliases":["136 kDa double-stranded RNA-binding protein","p136","Interferon-inducible protein 4","IFI-4","K88DSRBP"],"length_aa":1226,"mass_kda":136.1,"function":"Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing (PubMed:12618436, PubMed:7565688, PubMed:7972084). This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins since the translational machinery read the inosine as a guanosine; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication","subcellular_location":"Cytoplasm; Nucleus; Nucleus, nucleolus","url":"https://www.uniprot.org/uniprotkb/P55265/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ADAR","classification":"Not Classified","n_dependent_lines":532,"n_total_lines":1208,"dependency_fraction":0.44039735099337746},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CAPZB","stoichiometry":0.2},{"gene":"COPB2","stoichiometry":0.2},{"gene":"CPSF6","stoichiometry":0.2},{"gene":"DDX21","stoichiometry":0.2},{"gene":"DHX9","stoichiometry":0.2},{"gene":"EIF2AK2","stoichiometry":0.2},{"gene":"G3BP2","stoichiometry":0.2},{"gene":"HNRNPL","stoichiometry":0.2},{"gene":"ILF3","stoichiometry":0.2},{"gene":"PSPC1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ADAR","total_profiled":1310},"omim":[{"mim_id":"615782","title":"CIRCADIAN-ASSOCIATED REPRESSOR OF TRANSCRIPTION; CIART","url":"https://www.omim.org/entry/615782"},{"mim_id":"615010","title":"AICARDI-GOUTIERES SYNDROME 6; AGS6","url":"https://www.omim.org/entry/615010"},{"mim_id":"612715","title":"DYSCHROMATOSIS UNIVERSALIS HEREDITARIA 2; DUH2","url":"https://www.omim.org/entry/612715"},{"mim_id":"609631","title":"RNA SENSOR RIGI; RIGI","url":"https://www.omim.org/entry/609631"},{"mim_id":"606754","title":"SAM DOMAIN- AND HD DOMAIN-CONTAINING PROTEIN 1; SAMHD1","url":"https://www.omim.org/entry/606754"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoli","reliability":"Enhanced"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ADAR"},"hgnc":{"alias_symbol":["ADAR1","DRADA"],"prev_symbol":["IFI4","G1P1"]},"alphafold":{"accession":"P55265","domains":[{"cath_id":"1.10.10.10","chopping":"149-189","consensus_level":"medium","plddt":88.041,"start":149,"end":189},{"cath_id":"1.10.10.10","chopping":"311-364","consensus_level":"high","plddt":90.0343,"start":311,"end":364},{"cath_id":"3.30.160.20","chopping":"493-574","consensus_level":"high","plddt":91.9224,"start":493,"end":574},{"cath_id":"-","chopping":"630-635_646-674","consensus_level":"medium","plddt":90.7537,"start":630,"end":674},{"cath_id":"3.30.160.20","chopping":"727-802","consensus_level":"high","plddt":83.0289,"start":727,"end":802},{"cath_id":"-","chopping":"841-861_868-1220","consensus_level":"high","plddt":89.0099,"start":841,"end":1220}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P55265","model_url":"https://alphafold.ebi.ac.uk/files/AF-P55265-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P55265-F1-predicted_aligned_error_v6.png","plddt_mean":68.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ADAR","jax_strain_url":"https://www.jax.org/strain/search?query=ADAR"},"sequence":{"accession":"P55265","fasta_url":"https://rest.uniprot.org/uniprotkb/P55265.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P55265/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P55265"}},"corpus_meta":[{"pmid":"20192758","id":"PMC_20192758","title":"Functions and regulation of RNA editing by ADAR deaminases.","date":"2010","source":"Annual review of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20192758","citation_count":1038,"is_preprint":false},{"pmid":"26275108","id":"PMC_26275108","title":"RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself.","date":"2015","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/26275108","citation_count":771,"is_preprint":false},{"pmid":"30559380","id":"PMC_30559380","title":"Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/30559380","citation_count":550,"is_preprint":false},{"pmid":"25456137","id":"PMC_25456137","title":"The RNA-editing enzyme ADAR1 controls innate immune responses to RNA.","date":"2014","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25456137","citation_count":545,"is_preprint":false},{"pmid":"25604658","id":"PMC_25604658","title":"Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1.","date":"2015","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/25604658","citation_count":507,"is_preprint":false},{"pmid":"29395325","id":"PMC_29395325","title":"Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown.","date":"2018","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/29395325","citation_count":454,"is_preprint":false},{"pmid":"34686350","id":"PMC_34686350","title":"ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34686350","citation_count":366,"is_preprint":false},{"pmid":"35614224","id":"PMC_35614224","title":"ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/35614224","citation_count":337,"is_preprint":false},{"pmid":"23273215","id":"PMC_23273215","title":"The ADAR protein family.","date":"2012","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/23273215","citation_count":278,"is_preprint":false},{"pmid":"33087935","id":"PMC_33087935","title":"Epigenetic therapy induces transcription of inverted SINEs and ADAR1 dependency.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33087935","citation_count":227,"is_preprint":false},{"pmid":"31308540","id":"PMC_31308540","title":"Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs.","date":"2019","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/31308540","citation_count":215,"is_preprint":false},{"pmid":"35859175","id":"PMC_35859175","title":"ADAR1 prevents autoinflammation by suppressing spontaneous ZBP1 activation.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/35859175","citation_count":211,"is_preprint":false},{"pmid":"35859177","id":"PMC_35859177","title":"ADAR1 mutation causes ZBP1-dependent immunopathology.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/35859177","citation_count":177,"is_preprint":false},{"pmid":"35859176","id":"PMC_35859176","title":"ADAR1 averts fatal type I interferon induction by ZBP1.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/35859176","citation_count":176,"is_preprint":false},{"pmid":"31404141","id":"PMC_31404141","title":"ADAR1: \"Editor-in-Chief\" of Cytoplasmic Innate Immunity.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31404141","citation_count":159,"is_preprint":false},{"pmid":"30710018","id":"PMC_30710018","title":"Adenosine deaminase acting on RNA (ADAR1), a suppressor of double-stranded RNA-triggered innate immune responses.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30710018","citation_count":143,"is_preprint":false},{"pmid":"20382028","id":"PMC_20382028","title":"ADAR editing in double-stranded UTRs and other noncoding RNA sequences.","date":"2010","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20382028","citation_count":135,"is_preprint":false},{"pmid":"34105255","id":"PMC_34105255","title":"The role of RNA editing enzyme ADAR1 in human disease.","date":"2021","source":"Wiley interdisciplinary reviews. RNA","url":"https://pubmed.ncbi.nlm.nih.gov/34105255","citation_count":121,"is_preprint":false},{"pmid":"33736931","id":"PMC_33736931","title":"ADAR RNA Modifications, the Epitranscriptome and Innate Immunity.","date":"2021","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33736931","citation_count":101,"is_preprint":false},{"pmid":"28913566","id":"PMC_28913566","title":"ADAR RNA editing in human disease; more to it than meets the I.","date":"2017","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28913566","citation_count":101,"is_preprint":false},{"pmid":"19472181","id":"PMC_19472181","title":"Origins and evolution of ADAR-mediated RNA editing.","date":"2009","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/19472181","citation_count":98,"is_preprint":false},{"pmid":"36198772","id":"PMC_36198772","title":"Modular, programmable RNA sensing using ADAR editing in living cells.","date":"2022","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/36198772","citation_count":97,"is_preprint":false},{"pmid":"34980913","id":"PMC_34980913","title":"CLUSTER guide RNAs enable precise and efficient RNA editing with endogenous ADAR enzymes in vivo.","date":"2022","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/34980913","citation_count":94,"is_preprint":false},{"pmid":"29129909","id":"PMC_29129909","title":"RNA editing by ADAR1 leads to context-dependent transcriptome-wide changes in RNA secondary structure.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29129909","citation_count":91,"is_preprint":false},{"pmid":"36302988","id":"PMC_36302988","title":"Programmable eukaryotic protein synthesis with RNA sensors by harnessing ADAR.","date":"2022","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/36302988","citation_count":85,"is_preprint":false},{"pmid":"33723056","id":"PMC_33723056","title":"Decoupling expression and editing preferences of ADAR1 p150 and p110 isoforms.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33723056","citation_count":85,"is_preprint":false},{"pmid":"36710220","id":"PMC_36710220","title":"ADAR1 and ZBP1 in innate immunity, cell death, and disease.","date":"2023","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36710220","citation_count":84,"is_preprint":false},{"pmid":"33972779","id":"PMC_33972779","title":"Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence.","date":"2021","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33972779","citation_count":80,"is_preprint":false},{"pmid":"35459560","id":"PMC_35459560","title":"ADAR1 and its implications in cancer development and treatment.","date":"2022","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/35459560","citation_count":79,"is_preprint":false},{"pmid":"30585209","id":"PMC_30585209","title":"ADAR1 Editing and its Role in Cancer.","date":"2018","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/30585209","citation_count":77,"is_preprint":false},{"pmid":"21728134","id":"PMC_21728134","title":"ADAR proteins: double-stranded RNA and Z-DNA binding domains.","date":"2012","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21728134","citation_count":75,"is_preprint":false},{"pmid":"21732238","id":"PMC_21732238","title":"Control of ADAR1 editing of hepatitis delta virus RNAs.","date":"2012","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21732238","citation_count":71,"is_preprint":false},{"pmid":"26612708","id":"PMC_26612708","title":"To edit or not to edit: regulation of ADAR editing specificity and efficiency.","date":"2015","source":"Wiley interdisciplinary reviews. RNA","url":"https://pubmed.ncbi.nlm.nih.gov/26612708","citation_count":69,"is_preprint":false},{"pmid":"31174840","id":"PMC_31174840","title":"ADAR and Immune Silencing in Cancer.","date":"2019","source":"Trends in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31174840","citation_count":67,"is_preprint":false},{"pmid":"35133980","id":"PMC_35133980","title":"ADAR1-mediated RNA editing links ganglioside catabolism to glioblastoma stem cell maintenance.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/35133980","citation_count":63,"is_preprint":false},{"pmid":"27999332","id":"PMC_27999332","title":"Functions of the RNA Editing Enzyme ADAR1 and Their Relevance to Human Diseases.","date":"2016","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/27999332","citation_count":63,"is_preprint":false},{"pmid":"21769729","id":"PMC_21769729","title":"ADAR proteins: structure and catalytic mechanism.","date":"2012","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21769729","citation_count":60,"is_preprint":false},{"pmid":"27658966","id":"PMC_27658966","title":"ADAR1 restricts LINE-1 retrotransposition.","date":"2016","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/27658966","citation_count":59,"is_preprint":false},{"pmid":"39030076","id":"PMC_39030076","title":"ADAR1: from basic mechanisms to inhibitors.","date":"2024","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/39030076","citation_count":58,"is_preprint":false},{"pmid":"24905200","id":"PMC_24905200","title":"An RNA editor, adenosine deaminase acting on double-stranded RNA (ADAR1).","date":"2014","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/24905200","citation_count":57,"is_preprint":false},{"pmid":"35851616","id":"PMC_35851616","title":"ADAR1 downregulation by autophagy drives senescence independently of RNA editing by enhancing p16INK4a levels.","date":"2022","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/35851616","citation_count":56,"is_preprint":false},{"pmid":"32433965","id":"PMC_32433965","title":"Unbiased Identification of trans Regulators of ADAR and A-to-I RNA Editing.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32433965","citation_count":54,"is_preprint":false},{"pmid":"24256817","id":"PMC_24256817","title":"ADAR enzyme and miRNA story: a nucleotide that can make the difference.","date":"2013","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24256817","citation_count":53,"is_preprint":false},{"pmid":"26692549","id":"PMC_26692549","title":"ADAR1, inosine and the immune sensing system: distinguishing self from non-self.","date":"2015","source":"Wiley interdisciplinary reviews. RNA","url":"https://pubmed.ncbi.nlm.nih.gov/26692549","citation_count":53,"is_preprint":false},{"pmid":"29457714","id":"PMC_29457714","title":"Selective Recognition of RNA Substrates by ADAR Deaminase Domains.","date":"2018","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29457714","citation_count":53,"is_preprint":false},{"pmid":"36803553","id":"PMC_36803553","title":"Reversal of malignant ADAR1 splice isoform switching with Rebecsinib.","date":"2023","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/36803553","citation_count":52,"is_preprint":false},{"pmid":"36688311","id":"PMC_36688311","title":"ADAR1 Non-Editing Function in Macrophage Activation and Abdominal Aortic Aneurysm.","date":"2023","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/36688311","citation_count":49,"is_preprint":false},{"pmid":"30290838","id":"PMC_30290838","title":"ADAR1-mediated RNA-editing of 3'UTRs in breast cancer.","date":"2018","source":"Biological research","url":"https://pubmed.ncbi.nlm.nih.gov/30290838","citation_count":48,"is_preprint":false},{"pmid":"32044725","id":"PMC_32044725","title":"Novel Engineered Programmable Systems for ADAR-Mediated RNA Editing.","date":"2020","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/32044725","citation_count":48,"is_preprint":false},{"pmid":"34496885","id":"PMC_34496885","title":"An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks.","date":"2021","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34496885","citation_count":47,"is_preprint":false},{"pmid":"35064076","id":"PMC_35064076","title":"Impact of ADAR-induced editing of minor viral RNA populations on replication and transmission of SARS-CoV-2.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35064076","citation_count":46,"is_preprint":false},{"pmid":"28106799","id":"PMC_28106799","title":"RNA Editing, ADAR1, and the Innate Immune Response.","date":"2017","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/28106799","citation_count":45,"is_preprint":false},{"pmid":"29855470","id":"PMC_29855470","title":"ADAR1-mediated regulation of melanoma invasion.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29855470","citation_count":43,"is_preprint":false},{"pmid":"37026479","id":"PMC_37026479","title":"The ADAR1 editome reveals drivers of editing-specificity for ADAR1-isoforms.","date":"2023","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/37026479","citation_count":43,"is_preprint":false},{"pmid":"28974449","id":"PMC_28974449","title":"Mechanisms and implications of ADAR-mediated RNA editing in cancer.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/28974449","citation_count":42,"is_preprint":false},{"pmid":"35898396","id":"PMC_35898396","title":"ADAR1-Mediated RNA Editing and Its Role in Cancer.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35898396","citation_count":39,"is_preprint":false},{"pmid":"34694399","id":"PMC_34694399","title":"ADAR Editing in Viruses: An Evolutionary Force to Reckon with.","date":"2021","source":"Genome biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/34694399","citation_count":38,"is_preprint":false},{"pmid":"36000401","id":"PMC_36000401","title":"ADAR1 Prevents Autoinflammatory Processes in the Heart Mediated by IRF7.","date":"2022","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/36000401","citation_count":38,"is_preprint":false},{"pmid":"27362366","id":"PMC_27362366","title":"ADAR1 deletion induces NFκB and interferon signaling dependent liver inflammation and fibrosis.","date":"2016","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/27362366","citation_count":38,"is_preprint":false},{"pmid":"10854778","id":"PMC_10854778","title":"Comparative analysis of the DRADA A-to-I RNA editing gene from mammals, pufferfish and zebrafish.","date":"2000","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/10854778","citation_count":35,"is_preprint":false},{"pmid":"37801857","id":"PMC_37801857","title":"ADAR1 exacerbates ischemic brain injury via astrocyte-mediated neuron apoptosis.","date":"2023","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/37801857","citation_count":33,"is_preprint":false},{"pmid":"29625900","id":"PMC_29625900","title":"ADAR1 and PKR, interferon stimulated genes with clashing effects on HIV-1 replication.","date":"2018","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/29625900","citation_count":32,"is_preprint":false},{"pmid":"36599932","id":"PMC_36599932","title":"ADAR1-dependent miR-3144-3p editing simultaneously induces MSI2 expression and suppresses SLC38A4 expression in liver cancer.","date":"2023","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36599932","citation_count":32,"is_preprint":false},{"pmid":"38160061","id":"PMC_38160061","title":"In search of critical dsRNA targets of ADAR1.","date":"2023","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/38160061","citation_count":31,"is_preprint":false},{"pmid":"27044320","id":"PMC_27044320","title":"The role of RNA editing by ADAR1 in prevention of innate immune sensing of self-RNA.","date":"2016","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/27044320","citation_count":31,"is_preprint":false},{"pmid":"38530197","id":"PMC_38530197","title":"Induction of Viral Mimicry Upon Loss of DHX9 and ADAR1 in Breast Cancer Cells.","date":"2024","source":"Cancer research communications","url":"https://pubmed.ncbi.nlm.nih.gov/38530197","citation_count":30,"is_preprint":false},{"pmid":"32396862","id":"PMC_32396862","title":"ADAR1-Dependent RNA Editing Promotes MET and iPSC Reprogramming by Alleviating ER Stress.","date":"2020","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/32396862","citation_count":30,"is_preprint":false},{"pmid":"37831098","id":"PMC_37831098","title":"ADAR1 links R-loop homeostasis to ATR activation in replication stress response.","date":"2023","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/37831098","citation_count":29,"is_preprint":false},{"pmid":"24008387","id":"PMC_24008387","title":"ADAR-mediated RNA editing in non-coding RNA sequences.","date":"2013","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24008387","citation_count":29,"is_preprint":false},{"pmid":"35586115","id":"PMC_35586115","title":"8-azaadenosine and 8-chloroadenosine are not selective inhibitors of ADAR.","date":"2021","source":"Cancer research communications","url":"https://pubmed.ncbi.nlm.nih.gov/35586115","citation_count":28,"is_preprint":false},{"pmid":"28398248","id":"PMC_28398248","title":"ADAR1 and MicroRNA; A Hidden Crosstalk in Cancer.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28398248","citation_count":26,"is_preprint":false},{"pmid":"30391332","id":"PMC_30391332","title":"ADAR RNA editing in innate immune response phasing, in circadian clocks and in sleep.","date":"2018","source":"Biochimica et biophysica acta. Gene regulatory mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/30391332","citation_count":25,"is_preprint":false},{"pmid":"37906879","id":"PMC_37906879","title":"Adenosine Deaminase Acting on RNA (ADAR) Enzymes: A Journey from Weird to Wondrous.","date":"2023","source":"Accounts of chemical research","url":"https://pubmed.ncbi.nlm.nih.gov/37906879","citation_count":25,"is_preprint":false},{"pmid":"39146181","id":"PMC_39146181","title":"An ADAR1 dsRBD3-PKR kinase domain interaction on dsRNA inhibits PKR activation.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39146181","citation_count":24,"is_preprint":false},{"pmid":"37718249","id":"PMC_37718249","title":"A-to-I RNA editing by ADAR and its therapeutic applications: From viral infections to cancer immunotherapy.","date":"2023","source":"Wiley interdisciplinary reviews. RNA","url":"https://pubmed.ncbi.nlm.nih.gov/37718249","citation_count":23,"is_preprint":false},{"pmid":"32169840","id":"PMC_32169840","title":"ADAR1 Regulates Early T Cell Development via MDA5-Dependent and -Independent Pathways.","date":"2020","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/32169840","citation_count":23,"is_preprint":false},{"pmid":"27937139","id":"PMC_27937139","title":"Effects of Aicardi-Goutières syndrome mutations predicted from ADAR-RNA structures.","date":"2016","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/27937139","citation_count":23,"is_preprint":false},{"pmid":"29396793","id":"PMC_29396793","title":"Post-transcriptional regulation of LINE-1 retrotransposition by AID/APOBEC and ADAR deaminases.","date":"2018","source":"Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology","url":"https://pubmed.ncbi.nlm.nih.gov/29396793","citation_count":22,"is_preprint":false},{"pmid":"28960389","id":"PMC_28960389","title":"The Other Face of an Editor: ADAR1 Functions in Editing-Independent Ways.","date":"2017","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/28960389","citation_count":21,"is_preprint":false},{"pmid":"28559490","id":"PMC_28559490","title":"ADAR RNA editing below the backbone.","date":"2017","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/28559490","citation_count":20,"is_preprint":false},{"pmid":"38866351","id":"PMC_38866351","title":"Loss of ADAR1 induces ferroptosis of breast cancer cells.","date":"2024","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/38866351","citation_count":20,"is_preprint":false},{"pmid":"39103360","id":"PMC_39103360","title":"An improved SNAP-ADAR tool enables efficient RNA base editing to interfere with post-translational protein modification.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39103360","citation_count":19,"is_preprint":false},{"pmid":"36972568","id":"PMC_36972568","title":"Selective Inhibition of ADAR1 Using 8-Azanebularine-Modified RNA Duplexes.","date":"2023","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36972568","citation_count":19,"is_preprint":false},{"pmid":"35697535","id":"PMC_35697535","title":"ADAR1 and AZIN1 RNA editing function as an oncogene and contributes to immortalization in endometrial cancer.","date":"2022","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35697535","citation_count":19,"is_preprint":false},{"pmid":"23949595","id":"PMC_23949595","title":"Antagonistic and stimulative roles of ADAR1 in RNA silencing.","date":"2013","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/23949595","citation_count":19,"is_preprint":false},{"pmid":"38785511","id":"PMC_38785511","title":"ADAR Family Proteins: A Structural Review.","date":"2024","source":"Current issues in molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/38785511","citation_count":18,"is_preprint":false},{"pmid":"36469491","id":"PMC_36469491","title":"The RNA-editing enzyme ADAR1: a regulatory hub that tunes multiple dsRNA-sensing pathways.","date":"2023","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36469491","citation_count":18,"is_preprint":false},{"pmid":"39149897","id":"PMC_39149897","title":"Rational design of base, sugar and backbone modifications improves ADAR-mediated RNA editing.","date":"2024","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/39149897","citation_count":18,"is_preprint":false},{"pmid":"38233935","id":"PMC_38233935","title":"The role of ADAR1 through and beyond its editing activity in cancer.","date":"2024","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/38233935","citation_count":16,"is_preprint":false},{"pmid":"34768866","id":"PMC_34768866","title":"Deciphering the Biological Significance of ADAR1-Z-RNA Interactions.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34768866","citation_count":16,"is_preprint":false},{"pmid":"31930087","id":"PMC_31930087","title":"ADAR, the carcinogenesis mechanisms of ADAR and related clinical applications.","date":"2019","source":"Annals of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31930087","citation_count":16,"is_preprint":false},{"pmid":"40185749","id":"PMC_40185749","title":"Cooperative role of PACT and ADAR1 in preventing aberrant PKR activation by self-derived double-stranded RNA.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40185749","citation_count":16,"is_preprint":false},{"pmid":"35711824","id":"PMC_35711824","title":"ADAR1 Prevents R-loop Accumulation-Driven ATR Pathway Activation in Ovarian Cancer.","date":"2022","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35711824","citation_count":16,"is_preprint":false},{"pmid":"35124003","id":"PMC_35124003","title":"ADAR1- and ADAR2-mediated regulation of maturation and targeting of miR-376b to modulate GABA neurotransmitter catabolism.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35124003","citation_count":16,"is_preprint":false},{"pmid":"30651342","id":"PMC_30651342","title":"ADAR1 Is Required for Dendritic Cell Subset Homeostasis and Alveolar Macrophage Function.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/30651342","citation_count":16,"is_preprint":false},{"pmid":"33846332","id":"PMC_33846332","title":"Learning cis-regulatory principles of ADAR-based RNA editing from CRISPR-mediated mutagenesis.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33846332","citation_count":16,"is_preprint":false},{"pmid":"40091520","id":"PMC_40091520","title":"ADAR1-HNRNPL-Mediated CircCANX Decline Promotes Autophagy in Chronic Obstructive Pulmonary Disease.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/40091520","citation_count":15,"is_preprint":false},{"pmid":"39572551","id":"PMC_39572551","title":"Dimerization of ADAR1 modulates site-specificity of RNA editing.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39572551","citation_count":15,"is_preprint":false},{"pmid":"39673305","id":"PMC_39673305","title":"Distinct interactomes of ADAR1 nuclear and cytoplasmic protein isoforms and their responses to interferon induction.","date":"2024","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/39673305","citation_count":15,"is_preprint":false},{"pmid":"38531645","id":"PMC_38531645","title":"Multifaceted roles of RNA editing enzyme ADAR1 in innate immunity.","date":"2024","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/38531645","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44807,"output_tokens":9305,"usd":0.136998,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19602,"output_tokens":8004,"usd":0.149055,"stage2_stop_reason":"end_turn"},"total_usd":0.286053,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2015,\n      \"finding\": \"A-to-I editing of endogenous dsRNA by ADAR1 is the essential function required to prevent activation of the cytosolic dsRNA sensor MDA5. Editing-deficient knock-in mice (E861A) died at ~E13.5 with activated interferon and dsRNA-sensing pathways; embryonic death was rescued by concurrent deletion of MDA5. Genome-wide analysis identified clustered hyperediting within long dsRNA stem loops in 3' UTRs of endogenous transcripts as primary ADAR1 substrates.\",\n      \"method\": \"Editing-deficient knock-in mouse (E861A), genetic rescue by MDA5 deletion, genome-wide substrate mapping\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vivo knock-in mutagenesis combined with genetic epistasis (MDA5 rescue) and genome-wide substrate identification, replicated across multiple labs\",\n      \"pmids\": [\"26275108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ADAR1 prevents translational shutdown by inhibiting hyperactivation of PKR, a dsRNA sensor. In ADAR1 knockout human cells, endogenous Alu elements in pol II-transcribed mRNAs were the primary editing substrates. Both dsRNA binding and catalytic activities of ADAR1 were required to fully prevent endogenous RNA from activating PKR. ADAR1 knockout neuronal progenitor cells exhibited MDA5-dependent spontaneous interferon production, PKR activation, and cell death.\",\n      \"method\": \"ADAR1 knockout human cells, mechanistic dissection with catalytic and dsRNA-binding mutants, cell-type specific phenotyping\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — KO cells with multiple orthogonal functional validations (catalytic mutant, dsRNA-binding mutant, PKR activation assay, MDA5 dependence), single lab but multiple methods\",\n      \"pmids\": [\"29395325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Adar1 embryonic lethality is rescued to live birth in Adar1;Mavs double mutants, demonstrating that the antiviral interferon induction response to cytoplasmic dsRNA drives the lethal phenotype. Restoring editing-active cytoplasmic ADAR1 dramatically reduced aberrant immune responses in Adar1 mutant MEFs. dsRNA oligonucleotides containing inosine-uracil base pairs reduced the aberrant innate immune response, consistent with inosine in cellular RNA inhibiting RLR interactions.\",\n      \"method\": \"Genetic rescue (double mutant mice), MEF transfection with inosine-containing dsRNA, reintroduction of editing-active ADAR1\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with double-mutant rescue and biochemical rescue in MEFs, replicated concept across multiple labs\",\n      \"pmids\": [\"25456137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ADAR1 inhibits spontaneous activation of ZBP1 by preventing accumulation of endogenous Z-form dsRNAs (Z-RNAs). The Zα domain of ADAR1 promotes A-to-I editing of endogenous Alu elements to prevent dsRNA formation through pairing of inverted Alu repeats, which can otherwise activate ZBP1. ZBP1 activation in ADAR1-deficient cells elicits caspase-8-dependent apoptosis and MLKL-mediated necroptosis. ZBP1 contributes to embryonic lethality of Adar-knockout mice.\",\n      \"method\": \"Adar knockout mice, Adar;Mavs double mutants, Zα domain mutation, cell death pathway analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic models with defined domain mutations, three independent papers published simultaneously confirm the same mechanism\",\n      \"pmids\": [\"35859175\", \"35859177\", \"35859176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The ZBD (Zα domain) point mutation of ADAR1 drives pathology through ZBP1 activation. Ablation of ZBP1 fully rescued overt pathology caused by ADAR1 Zα domain alteration. Loss of RIPK3 partially phenocopied ZBP1 ablation, while combined deletion of caspase-8 and RIPK3, or caspase-8 and MLKL, exacerbated pathogenic effects, indicating ZBP1-dependent signaling underlies the autoinflammatory pathology.\",\n      \"method\": \"Genetic epistasis in mice: Adar1 ZBD mutant crossed with ZBP1 KO, RIPK3 KO, caspase-8/RIPK3 double KO, caspase-8/MLKL double KO\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — rigorous in vivo epistasis with multiple genetic combinations, independently replicated by two other simultaneous Nature papers\",\n      \"pmids\": [\"35859177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ADAR1 Zα domain prevents endogenous Z-RNA-dependent activation of ZBP1 that drives type I IFN responses. ZBP1 deficiency or mutation of its Zα domains reduced IFN-stimulated gene expression and prevented early postnatal lethality in Adar1mZα/- mice. ZBP1 promoted IFN activation independently of RIPK1, RIPK3, MLKL-mediated necroptosis and caspase-8-dependent apoptosis, suggesting a novel signaling mechanism. Adar1mZα/- mice showed upregulation and impaired editing of endogenous retroelement-derived complementary RNA reads as a likely Z-RNA source.\",\n      \"method\": \"Adar1mZα/- mouse model, ZBP1 deficiency rescue, Zα domain mutation of ZBP1, RNA sequencing\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo epistasis with domain-specific mutations, independently confirmed by two simultaneously published Nature papers\",\n      \"pmids\": [\"35859176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ADAR1 prevents accumulation of endogenous Z-RNA elements enriched in 3' UTRs of interferon-stimulated mRNAs. Depletion or mutation of ADAR1 resulted in Z-RNA accumulation and activation of the Z-RNA sensor ZBP1, culminating in RIPK3-mediated necroptosis. ADAR1 interaction with ZBP1 Zα2 domain limits ZBP1 and RIPK3 interactions, suppressing PANoptosis.\",\n      \"method\": \"ADAR1 depletion, Z-RNA detection, ZBP1 activation assay, RIPK3 functional analysis, co-immunoprecipitation of ADAR1 with ZBP1\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (Z-RNA detection, Co-IP, genetic rescue), results confirmed across multiple simultaneous publications\",\n      \"pmids\": [\"35614224\", \"34686350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ADAR1 suppresses ZBP1-mediated PANoptosis by directly interacting with the Zα2 domain of ZBP1, limiting ZBP1-RIPK3 interactions. Combining interferons and nuclear export inhibitors activates ZBP1-dependent PANoptosis. Adar1fl/fl LysMcre mice are resistant to development of colorectal cancer and melanoma, but deletion of the ZBP1 Zα2 domain restores tumorigenesis.\",\n      \"method\": \"Co-immunoprecipitation, genetic mouse models (Adar1 conditional KO, ZBP1 Zα2 domain deletion), tumor models\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP demonstrating direct interaction, combined with in vivo epistasis in tumor models with domain-specific deletion\",\n      \"pmids\": [\"34686350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ADAR1 dsRBD3 directly interacts with the PKR kinase domain on dsRNA to inhibit PKR activation. AlphaFold modeling predicted an inhibitory ADAR1 dsRBD3-PKR kinase domain interaction on dsRNA. Wild-type or editing-inactive human ADAR1 expressed in A549 cells inhibited activation of endogenous PKR. ADAR1 dsRNA binding is required but not sufficient for PKR inhibition; mutating the ADAR1 dsRBD3-PKR contact prevented co-immunoprecipitation, PKR inhibition, and co-localization. Adar Mavs Eifak2 (Pkr) triple mutant mice rescued all defects and showed long-term survival.\",\n      \"method\": \"Co-immunoprecipitation, editing-inactive ADAR1 mutant, dsRBD3-PKR contact mutant, AlphaFold structural modeling, triple-mutant mouse model\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct interaction mapped by mutagenesis with structural model, editing-inactive mutant shows editing-independence, in vivo genetic rescue confirms pathway\",\n      \"pmids\": [\"39146181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PACT cooperates with ADAR1 to suppress PKR activation by self-dsRNAs. Simultaneous deletion of PACT and ADAR1 results in synthetic lethality, fully rescued in PKR-deficient cells. PACT-deficient cells hyperactivate PKR in response to RNA viruses.\",\n      \"method\": \"FACS-based genome-wide CRISPR-Cas9 knockout screen (CRISPR-Translate), double KO synthetic lethality, PKR KO rescue\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide screen with genetic epistasis (synthetic lethality rescued by PKR KO), orthogonal functional validation\",\n      \"pmids\": [\"40185749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ADAR1 p150 and p110 have distinct editing preferences determined primarily by their intracellular localization, not by the Zα domain. More than half of A-to-I edit sites are selectively edited by p150, while the other half are edited by either p150 or p110. p110 is co-expressed with p150 from the canonical p150-encoding mRNA due to leaky ribosome scanning downstream of the p150 start codon.\",\n      \"method\": \"ADAR1 KO cells reconstituted with modified isoform-selective constructs, RNA editing analysis, synonymous mutation to prevent leaky scanning\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — isoform-selective reconstitution in KO cells with genome-wide editing analysis and mechanistic follow-up on translation initiation\",\n      \"pmids\": [\"33723056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Isoform-specific editing by ADAR1 is primarily directed by intracellular localization (cytoplasmic p150 vs. nuclear p110), with ZBDα only minimally contributing to p150-specific editing preferences. ADAR1p110 preferentially binds and edits intronic sequences while ADAR1p150 preferentially binds and edits 3' UTRs.\",\n      \"method\": \"Transfection of ADAR1 isoforms into ADAR-less mouse cells, localization mutants, Zα domain mutants, RIP-seq\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — isoform and localization mutant analysis with RIP-seq, complemented by genome-wide editing analysis\",\n      \"pmids\": [\"37026479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ADAR1 is downregulated by autophagic degradation during cellular senescence, driving senescence through p16INK4a upregulation in an RNA-editing-independent manner. Mechanistically, ADAR1 promotes SIRT1 expression by affecting its RNA stability through HuR. SIRT1 antagonizes translation of mRNA encoding p16INK4a. ADAR1 downregulation is sufficient to drive senescence both in vitro and in vivo.\",\n      \"method\": \"Autophagic degradation assay, ADAR1 KD/KO in vitro and in vivo, editing-inactive mutant, HuR interaction, SIRT1/p16INK4a pathway analysis\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — editing-inactive mutant establishes editing-independence, pathway dissected with multiple orthogonal methods in vitro and in vivo\",\n      \"pmids\": [\"35851616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ADAR1 controls ITGB3 expression and melanoma cell invasiveness via editing-independent mechanisms: ADAR1 regulates miR-22 expression through FOXD1 transcription factor, and miR-22 directly regulates ITGB3 expression. ADAR1 also regulates ITGB3 at the transcriptional level via PAX6. Re-expression of either wild-type or catalytically inactive ADAR1 reversed the enhanced invasion caused by ADAR1 silencing.\",\n      \"method\": \"ADAR1 silencing/re-expression, catalytically inactive ADAR1 mutant, ITGB3 antibody blockade, miR-22/FOXD1/PAX6 pathway analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — catalytically inactive mutant establishes editing-independence, multiple downstream pathway components validated\",\n      \"pmids\": [\"29855470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ADAR1 interacts with TOPBP1 and facilitates TOPBP1 loading on perturbed replication forks by enhancing TOPBP1 association with RAD9 of the 9-1-1 complex, thereby promoting ATR activation. When replication is inhibited, DNA-RNA hybrids (R-loops) compete with TOPBP1 for ADAR1 binding, causing ADAR1 translocation from damaged forks to R-loop regions where it recruits RNA helicases DHX9 and DDX21 to unwind R-loops. ADAR1's dsRNA-binding domains are required for this function.\",\n      \"method\": \"Co-immunoprecipitation, proximity ligation, ADAR1 dsRBD mutants, R-loop detection (S9.6 antibody), ATR activation assays, helicase interaction studies\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple Co-IPs with defined domain mutants, mechanistic pathway dissected with orthogonal methods\",\n      \"pmids\": [\"37831098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ADAR1 suppresses LINE-1 (L1) retrotransposition independently of its editing activity. ADAR1 was found in the basal L1 RNP complex. By dual-tag affinity purification during HIV-1 expression, 14 non-ribosomal ADAR1-interacting proteins were identified, many associated with LINE-1 ribonucleoparticles.\",\n      \"method\": \"Dual-tag affinity purification, mass spectrometry, cell-culture retrotransposition assays (editing-inactive ADAR1 mutant)\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — editing-independent mechanism established with editing-inactive mutant and direct binding to L1 RNP shown, single lab\",\n      \"pmids\": [\"27658966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ADAR1 interacts with Drosha to promote its degradation, attenuating Drosha-DGCR8 interaction and consequently inhibiting pri- to pre-microRNA processing of microRNAs targeting IKKβ. This results in increased IKKβ expression and enhanced NF-κB signaling in macrophages, promoting vascular inflammation. This function is editing-independent.\",\n      \"method\": \"Co-immunoprecipitation (ADAR1-Drosha interaction), macrophage-specific ADAR1 KO, aortic transplantation, human AAA specimens, humanized AAA model\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP demonstrating ADAR1-Drosha interaction, validated in vivo in multiple mouse models and human tissue\",\n      \"pmids\": [\"36688311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ADAR1 forms a complex with Dicer via direct protein-protein interaction. ADAR1 in the Dicer complex promotes pre-miRNA cleavage by Dicer and facilitates miRNA loading onto RISC, stimulating miRNA processing and RNAi. ADAR1 differentiates its functions by forming either ADAR1 homodimers or Dicer-ADAR1 heterodimers. miRNA expression is globally inhibited in ADAR1-null mouse embryos.\",\n      \"method\": \"Co-immunoprecipitation, in vitro Dicer cleavage assay, ADAR1-null mouse embryo analysis\",\n      \"journal\": \"RNA biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus functional assay plus in vivo phenotype, single lab\",\n      \"pmids\": [\"23949595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ILF3, ILF2, STRBP, and ZFR (DZF-domain-containing proteins) interact with ADAR1 and ADAR2 and modulate RNA editing levels. ILF3 functions as a broadly influential negative regulator of editing. These were identified as trans regulators by BioID proximity labeling followed by mass spectrometry.\",\n      \"method\": \"BioID proximity labeling, mass spectrometry, ENCODE data validation, siRNA knockdown of identified interactors with editing level measurement\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — BioID plus functional validation of editing regulation, single lab\",\n      \"pmids\": [\"32433965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ADAR1 nuclear (p110) and cytoplasmic (p150) isoforms have distinct protein interactomes. Nuclear proteins are stable interactors with both isoforms. ADAR1p110 associates with nuclear components while ADAR1p150 associates with cytoplasmic cellular condensates. dsRNA binding is important for ADAR1 interactions. IFN treatment results in novel interactions, and during IFN response with poly(I:C), ADAR1p150 proximal network associates with antiviral stress granule components.\",\n      \"method\": \"Co-IP of endogenous ADAR1, Strep-tag Co-IP, BioID with individual isoforms, RNase A digestion, dsRNA-binding mutant\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — three orthogonal methods (endogenous Co-IP, tag Co-IP, BioID) with dsRNA-binding mutant controls to distinguish direct vs. RNA-mediated interactions\",\n      \"pmids\": [\"39673305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ADAR1 dsRBD3 forms a stable homodimer, and dimerization disruption via interface mutation does not abrogate editing activity but intricately affects editing efficiency at selected sites, indicating dimerization regulates site specificity rather than global catalytic activity.\",\n      \"method\": \"Crystal structure of ADAR1 dsRBD3, interface mutagenesis, in vitro editing assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure combined with mutagenesis and in vitro editing assay, single lab\",\n      \"pmids\": [\"39572551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The ADAR1 deaminase domain (hADAR1d) has different substrate selectivity from ADAR2. A chimeric protein bearing an RNA-binding loop from hADAR2d grafted onto hADAR1d showed ADAR2-like selectivity, demonstrating that substrate selectivity originates primarily from the deaminase domain RNA-binding loop. High-throughput mutagenesis (Sat-FACS-Seq) identified essential amino acids in an RNA-binding loop of hADAR1d.\",\n      \"method\": \"In vitro deamination assays, chimeric domain swap, Sat-FACS-Seq high-throughput mutagenesis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with domain swaps and systematic mutagenesis, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"29457714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ADAR1-dependent RNA editing of the 3'-UTR of GM2A (ganglioside catabolism activator) is critical for GBM stem cell self-renewal and stemness. ADAR1 inactivation or JAK/STAT pathway inhibition via TYK2 inhibition impaired GSC self-renewal. ADAR1 and global RNA editomes are elevated in GSCs compared with normal neural stem cells.\",\n      \"method\": \"ADAR1 inactivation, TYK2 inhibition, functional assays (self-renewal, stemness), 3'-UTR editing analysis of GM2A\",\n      \"journal\": \"Journal of Clinical Investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional KO with specific editing substrate identified (GM2A 3'-UTR), upstream pathway (JAK/STAT-TYK2) tested, single lab\",\n      \"pmids\": [\"35133980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ADAR1 editing-dependent RNA modification of CDK13 coding sequence (c.308A>G) promotes cancer cell hallmarks in thyroid cancer. This editing event increases nucleolar abundance of CDK13 protein and contributes to global changes in splicing produced by ADAR1 deregulation.\",\n      \"method\": \"Whole transcriptome sequencing, ADAR1 silencing, cell viability/proliferation/invasion assays, subnuclear localization analysis\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific editing site identified with functional consequences measured, single lab with multiple cell-based assays\",\n      \"pmids\": [\"34496885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ADAR1-dependent editing of miR-3144-3p at position 3 in the seed region redirects its targeting: edited miR-3144-3p upregulates MSI2 (by no longer suppressing it) and suppresses SLC38A4, contributing to hepatocellular carcinogenesis.\",\n      \"method\": \"RNA editing site identification, miRNA mimic transfection, target validation by luciferase/Western, ADAR1 siRNA/KO, mouse tumor model\",\n      \"journal\": \"Experimental & Molecular Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific editing site mechanistically linked to miRNA retargeting with in vivo validation, single lab\",\n      \"pmids\": [\"36599932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ADAR1 editing of dsRNA prevents MDA5 sensing and sequestration of dsRNAs encoding membrane proteins that promote ER homeostasis. Absence of ADAR1-dependent editing induces aberrant innate immune responses through MDA5, unleashing ER stress and hindering epithelial fate acquisition during MET and iPSC reprogramming. The PERK-dependent unfolded protein response pathway is activated downstream.\",\n      \"method\": \"ADAR1 KO and chemical inhibition during reprogramming, MDA5 KO rescue, ER stress markers, PERK pathway analysis\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic rescue with MDA5 KO demonstrates epistasis, mechanistic pathway connected, single lab\",\n      \"pmids\": [\"32396862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ADAR1 interacts with DHX9 in ovarian cancer cells to regulate R-loop complex formation. Loss of ADAR1 causes R-loop abnormal accumulation, contributing to single-strand DNA breaks and ATR pathway activation. A-to-I editing of nascent RNA by ADAR1 suppresses R-loop formation during co-transcriptional processes.\",\n      \"method\": \"Co-immunoprecipitation (ADAR1-DHX9), R-loop detection, ATR activation assays, ADAR1 silencing, cell cycle analysis\",\n      \"journal\": \"Journal of Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus functional R-loop and ATR assays, single lab\",\n      \"pmids\": [\"35711824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ADAR1-mediated A-to-I editing globally alters RNA secondary structure in a context-dependent manner. ADAR1 silencing results in a lower global double-stranded to single-stranded RNA ratio, meaning editing can stabilize a large subset of imperfect RNA duplexes (inverted Alus in UTRs). The destabilized duplexes are predominantly cytoplasmic and show higher ribosomal occupancy.\",\n      \"method\": \"Parallel analysis of RNA structure sequencing (PARS-seq) in ADAR1-deficient cells\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide structural analysis method (PARS-seq) in KD cells, single lab\",\n      \"pmids\": [\"29129909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ADAR1 p150 is an IFN-inducible isoform found in both cytoplasm and nucleus, while ADAR1 p110 is constitutively expressed and nuclear. ADAR1-dependent A-to-I editing can alter RNA structure stability, mRNA coding, and splicing; inosine is decoded as guanosine by ribosomes and polymerases.\",\n      \"method\": \"Isoform characterization via alternative promoter analysis, fractionation, biochemical assays\",\n      \"journal\": \"Journal of Interferon & Cytokine Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical fractionation and isoform characterization, foundational mechanistic description replicated across many labs\",\n      \"pmids\": [\"24905200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Loss of ADAR1 in breast cancer cells induces ferroptosis via a miR-335-5p/Sp1/GPX4 pathway. ADAR1 controls miR-335-5p levels; reduced ADAR1 increases miR-335-5p which targets Sp1, a transcription factor for GPX4, leading to decreased GPX4 and ferroptosis. This function is independent of ADAR1's RNA editing activity.\",\n      \"method\": \"CRISPR-Cas9 KO and plasmid overexpression of ADAR1, miR-335-5p measurements, ROS/MDA/GSH/Fe2+ assays, GPX4 protein levels\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO with pathway validation and editing-independent conclusion, single lab\",\n      \"pmids\": [\"38866351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ADAR1 prevents autoinflammatory myocarditis in cardiomyocytes via IRF7 as the main mediator. Enzymatic RNA editing activity prevents IRF7-mediated autoinflammatory reactions triggered by endogenous non-edited RNAs via MDA5; additionally ADAR1 serves editing-independent roles required for long-term cardiac function.\",\n      \"method\": \"Cardiomyocyte-specific Adar1 KO mice, MDA5 (Ifih1) KO rescue, Irf7 KO rescue, catalytically inactive ADAR1 in Ifih1 mutant background\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple epistasis crosses with catalytically inactive mutant to separate editing-dependent from -independent roles, in vivo cardiac phenotype\",\n      \"pmids\": [\"36000401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ADAR1 establishes a negative-feedback loop restricting the viral mimicry response to epigenetic therapy. Intronic and intergenic SINE elements (inverted-repeat Alus) are the major source of drug-induced immunogenic dsRNA. ADAR1 targets and destabilizes inverted-repeat Alu dsRNA, preventing MDA5 receptor activation. Depletion of ADAR1 in patient-derived cancer cells potentiates epigenetic therapy efficacy.\",\n      \"method\": \"Epigenetic drug treatment, ADAR1 depletion, dsRNA immunofluorescence, MDA5 activation assays, tumor growth assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — identified specific RNA species (inverted-repeat Alus) as ADAR1 substrates in drug context, functional rescue and patient-derived cells\",\n      \"pmids\": [\"33087935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ADAR1 p150 editing activity prevents MDA5-mediated sensing in cardiomyocytes through its RNA editing activity, while ADAR1 p110 does not contribute to this function. The Zα domain-Z-RNA interaction is required for p150 editing specificity at certain sites critical for preventing MDA5 activation.\",\n      \"method\": \"Isoform-specific mouse mutants, MDA5 (Ifih1) KO rescue, Zα domain point mutation (W197A)\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific mouse models with Zα domain mutation, single lab, confirmed by other groups using similar models\",\n      \"pmids\": [\"34768866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ADAR1-mediated editing of miR-376b-3p in the seed region redirects its target mRNAs to include 4-aminobutyrate aminotransferase (ABAT), the enzyme for GABA catabolism. Edited miR-376b-3p expression increases intracellular GABA levels and cell surface GABA type A receptors. ADAR2 negatively regulates miR-376b-3p maturation in an editing-independent manner.\",\n      \"method\": \"ADAR1/ADAR2 editing analysis of miRNA precursors and mature forms, miRNA target prediction and validation, GABA measurement, GABA-A receptor surface expression\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific editing-dependent retargeting validated functionally, editing-independent ADAR2 effect also shown, single lab\",\n      \"pmids\": [\"35124003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ADAR1 requires RNA editing activity to regulate early thymocyte development in part through MDA5 (concurrent MDA5 deletion ameliorated apoptosis but did not restore impaired transition and TCR expression), indicating RNA-editing-dependent and -independent functions of ADAR1 synergistically regulate early thymocyte development.\",\n      \"method\": \"Early thymocyte-specific ADAR1 conditional KO, MDA5 KO rescue, forced TCR expression rescue experiments\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with multiple rescue experiments distinguishing editing-dependent from -independent roles, single lab\",\n      \"pmids\": [\"32169840\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ADAR1 is an RNA editing enzyme that converts adenosine to inosine (A-to-I) in double-stranded RNA substrates via its deaminase domain, with two isoforms (IFN-inducible cytoplasmic p150 and constitutive nuclear p110) that have distinct substrate preferences determined by their localization and Zα domain; its primary essential function is to mark endogenous dsRNAs (especially inverted Alu repeat-containing transcripts) with inosine to prevent their recognition as 'nonself' by cytosolic sensors MDA5, PKR, and ZBP1—with editing-dependent inhibition of MDA5 preventing interferon induction, direct dsRBD3-mediated inhibition of PKR kinase domain preventing translational shutdown, and Zα domain-mediated editing of Z-RNA substrates preventing ZBP1-driven PANoptosis/necroptosis—while also performing editing-independent functions including direct interaction with Dicer to stimulate miRNA processing, interaction with Drosha to promote its degradation (regulating NF-κB via microRNA processing), interaction with TOPBP1/RAD9 to promote ATR activation and R-loop clearance via DHX9/DDX21 recruitment, and autophagic degradation-mediated regulation of senescence through a SIRT1/p16INK4a axis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ADAR1 is an adenosine-to-inosine RNA editing enzyme whose essential physiological role is to mark endogenous double-stranded RNAs—especially long stem-loops formed by inverted Alu/SINE repeats in 3' UTRs and intronic regions—with inosine so they are not misread as 'nonself' by cytosolic dsRNA sensors [#0, #1, #31]. Editing-dead knock-in mice die in utero with runaway interferon signaling, and this lethality is rescued by deleting the dsRNA sensor MDA5 or the downstream adaptor MAVS, establishing that A-to-I editing destabilizes immunogenic duplexes and prevents MDA5/RLR activation [#0, #2, #30]. Beyond MDA5, ADAR1 restrains two additional sensors: its dsRBD3 directly contacts the PKR kinase domain on dsRNA to block PKR-driven translational shutdown (an interaction requiring dsRNA binding but independent of catalysis, with PACT acting as a cooperating suppressor) [#8, #9], and its Zα domain promotes editing of Z-form RNAs while directly binding the ZBP1 Zα2 domain to prevent ZBP1-driven necroptosis, apoptosis, and PANoptosis [#3, #6, #7]. Two isoforms—the IFN-inducible, partly cytoplasmic p150 and the constitutive nuclear p110—arise from leaky ribosome scanning of a shared mRNA, and their distinct editing site preferences (p150 favoring 3' UTRs, p110 favoring introns) are dictated chiefly by subcellular localization rather than the Zα domain [#10, #11, #28]. Substrate selectivity is encoded in an RNA-binding loop of the deaminase domain, and dsRBD3 homodimerization tunes site-specific editing efficiency [#20, #21]. ADAR1 also executes editing-independent functions: it stimulates Dicer-dependent pre-miRNA processing and RISC loading, promotes Drosha degradation to control NF-κB-linked microRNA biogenesis, and facilitates TOPBP1 loading and DHX9/DDX21-mediated R-loop resolution to support ATR activation at perturbed replication forks [#16, #17, #14, #26]. Through these activities ADAR1 governs interferon homeostasis, cell-death programs, miRNA biology, and genome stability, and its dysregulation is linked to senescence via a SIRT1/p16INK4a axis and to tumor cell fitness in multiple cancers [#12, #22, #31].\",\n  \"teleology\": [\n    {\n      \"year\": 2014,\n      \"claim\": \"Established that the lethal consequence of ADAR1 loss is driven by an aberrant antiviral interferon response to cytoplasmic dsRNA, and that inosine in cellular RNA directly dampens RLR-type sensing.\",\n      \"evidence\": \"Adar1;Mavs double-mutant mice, MEF reconstitution with editing-active ADAR1, and transfection of inosine-containing dsRNA\",\n      \"pmids\": [\"25456137\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify which specific sensor downstream of MAVS is engaged\", \"Endogenous substrate identity not mapped\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined the two ADAR1 isoforms (IFN-inducible p150, constitutive nuclear p110) and the molecular consequences of inosine, framing editing as a modifier of RNA structure, coding, and splicing.\",\n      \"evidence\": \"Alternative promoter analysis, subcellular fractionation, biochemical isoform characterization\",\n      \"pmids\": [\"24905200\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not resolve isoform-specific substrate preferences\", \"Did not link isoforms to specific sensor pathways\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Pinpointed editing of endogenous long-stem dsRNA as the single essential ADAR1 function preventing MDA5 activation, by showing MDA5 deletion rescues editing-dead mice.\",\n      \"evidence\": \"Editing-deficient E861A knock-in mice, genetic rescue by MDA5 deletion, genome-wide substrate mapping\",\n      \"pmids\": [\"26275108\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address non-MDA5 sensors\", \"Editing-independent roles not examined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealed an editing-independent role in suppressing LINE-1 retrotransposition and provided a first interactome anchored in L1 ribonucleoprotein complexes.\",\n      \"evidence\": \"Dual-tag affinity purification/MS, retrotransposition assays with editing-inactive ADAR1\",\n      \"pmids\": [\"27658966\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of L1 suppression not defined\", \"Single lab, no in vivo confirmation\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated that ADAR1 prevents PKR-driven translational shutdown, requiring both dsRNA binding and catalysis, and that Alu elements in pol II transcripts are the principal substrates.\",\n      \"evidence\": \"ADAR1 KO human cells with catalytic and dsRNA-binding mutants, PKR activation assays, neuronal progenitor phenotyping\",\n      \"pmids\": [\"29395325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve whether PKR inhibition is direct or substrate-mediated\", \"Cell-type dependence of phenotypes incompletely explained\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Localized substrate selectivity to an RNA-binding loop within the deaminase domain, distinguishing ADAR1 from ADAR2 specificity.\",\n      \"evidence\": \"In vitro deamination, ADAR1d/ADAR2d chimeric domain swap, Sat-FACS-Seq mutagenesis\",\n      \"pmids\": [\"29457714\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address how full-length context or dsRBDs modulate selectivity in cells\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed editing-independent control of cell invasiveness through transcriptional and miRNA-mediated regulation of ITGB3 in melanoma.\",\n      \"evidence\": \"ADAR1 silencing/re-expression with catalytically inactive mutant, miR-22/FOXD1/PAX6 pathway analysis, ITGB3 blockade\",\n      \"pmids\": [\"29855470\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ADAR1 regulates FOXD1/PAX6 mechanistically not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Connected ADAR1 to genome-wide RNA structure, showing editing can stabilize a large subset of cytoplasmic imperfect duplexes that influence ribosome occupancy.\",\n      \"evidence\": \"PARS-seq in ADAR1-deficient cells\",\n      \"pmids\": [\"29129909\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Correlational structure changes not tied to specific functional outcomes\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established ADAR1 as a brake on therapy-induced viral mimicry, identifying inverted-repeat Alu dsRNA as the drug-induced immunogenic species it destabilizes.\",\n      \"evidence\": \"Epigenetic drug treatment, ADAR1 depletion, dsRNA imaging, MDA5 activation and tumor assays in patient-derived cells\",\n      \"pmids\": [\"33087935\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish whether p150 or p110 mediates the negative feedback\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Linked ADAR1 editing to cell-fate programs by showing MDA5-driven innate immunity and ER stress block epithelial reprogramming when editing is lost.\",\n      \"evidence\": \"ADAR1 KO/inhibition during reprogramming, MDA5 KO rescue, PERK/UPR markers\",\n      \"pmids\": [\"32396862\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of sequestered ER-protein-encoding dsRNAs not fully resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed both editing-dependent (MDA5-linked) and editing-independent ADAR1 functions cooperate in early thymocyte development.\",\n      \"evidence\": \"Thymocyte-specific Adar1 KO, MDA5 KO rescue, forced TCR expression rescue\",\n      \"pmids\": [\"32169840\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Editing-independent function molecularly undefined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified DZF-domain proteins, especially ILF3, as trans-acting regulators that modulate ADAR-mediated editing levels.\",\n      \"evidence\": \"BioID proximity labeling/MS, ENCODE validation, siRNA knockdown with editing readouts\",\n      \"pmids\": [\"32433965\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which ILF3 negatively regulates editing not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed isoform editing preferences are set primarily by localization rather than the Zα domain, and that p110 co-arises from leaky scanning of the p150 mRNA.\",\n      \"evidence\": \"Isoform-selective reconstitution in ADAR1 KO cells, synonymous mutation to block leaky scanning, genome-wide editing analysis\",\n      \"pmids\": [\"33723056\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not quantify functional consequences of p110 from leaky scanning in vivo\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated a direct ADAR1–ZBP1 Zα2 interaction that limits ZBP1-RIPK3 engagement and suppresses PANoptosis, with tumor-relevant consequences.\",\n      \"evidence\": \"Co-IP, Adar1 conditional KO and ZBP1 Zα2 deletion mice, colorectal/melanoma tumor models\",\n      \"pmids\": [\"34686350\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of editing vs direct binding to ZBP1 control not fully separated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Provided an editing-dependent cancer mechanism via CDK13 coding-site editing that alters its nucleolar abundance and global splicing in thyroid cancer.\",\n      \"evidence\": \"Whole-transcriptome sequencing, ADAR1 silencing, proliferation/invasion assays, subnuclear localization\",\n      \"pmids\": [\"34496885\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal link between CDK13 editing and splicing changes not fully isolated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established the Zα domain–ZBP1 axis as the third sensor pathway restrained by ADAR1, with editing of Z-RNAs from inverted Alus/retroelements preventing ZBP1-driven necroptosis and apoptosis in vivo.\",\n      \"evidence\": \"Adar knockout and Zα-mutant mice, ZBP1/RIPK3/caspase-8/MLKL epistasis crosses, Z-RNA detection\",\n      \"pmids\": [\"35859175\", \"35859177\", \"35859176\", \"35614224\", \"34686350\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Exact Z-RNA structural features sensed not fully defined\", \"ZBP1 IFN-induction mechanism reported as RIPK-independent but not molecularly resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Distinguished editing-dependent (MDA5/IRF7) from editing-independent ADAR1 roles in cardiomyocyte homeostasis using catalytically inactive mutants in vivo.\",\n      \"evidence\": \"Cardiomyocyte-specific Adar1 KO, Ifih1 and Irf7 KO rescues, catalytically inactive ADAR1 in Ifih1-null background\",\n      \"pmids\": [\"36000401\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular identity of the editing-independent cardiac function undefined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed editing-independent downregulation of ADAR1 during senescence drives p16INK4a via a SIRT1/HuR axis.\",\n      \"evidence\": \"Autophagic degradation assays, ADAR1 KD/KO in vitro and in vivo, editing-inactive mutant, HuR/SIRT1/p16INK4a analysis\",\n      \"pmids\": [\"35851616\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How HuR-ADAR1 stabilizes SIRT1 mRNA mechanistically not detailed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated an editing-dependent oncogenic dependency in glioblastoma stem cells through GM2A 3'-UTR editing downstream of JAK/STAT-TYK2.\",\n      \"evidence\": \"ADAR1 inactivation, TYK2 inhibition, self-renewal assays, GM2A 3'-UTR editing analysis\",\n      \"pmids\": [\"35133980\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which GM2A editing supports stemness not resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Assigned the p150 isoform, via Zα-Z-RNA-guided editing specificity, as the responsible isoform preventing MDA5 activation in cardiomyocytes.\",\n      \"evidence\": \"Isoform-specific mouse mutants, Ifih1 KO rescue, Zα W197A point mutation\",\n      \"pmids\": [\"34768866\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Why p110 cannot substitute not fully explained\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Provided an editing-dependent miRNA-retargeting mechanism in hepatocellular carcinoma via miR-3144-3p seed editing.\",\n      \"evidence\": \"Editing site identification, miRNA mimic transfection, MSI2/SLC38A4 target validation, mouse tumor model\",\n      \"pmids\": [\"36599932\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Contribution relative to ADAR1's immune functions in HCC not assessed\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Refined isoform substrate preferences, showing localization (cytoplasmic p150 vs nuclear p110) drives 3'UTR vs intronic editing with only minor Zα contribution.\",\n      \"evidence\": \"ADAR1 isoform transfection into ADAR-less cells, localization and Zα mutants, RIP-seq\",\n      \"pmids\": [\"37026479\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of intronic p110 editing not detailed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed an editing-independent genome-stability role: ADAR1 promotes TOPBP1 loading and ATR activation at stalled forks and is redeployed to clear R-loops via DHX9/DDX21.\",\n      \"evidence\": \"Co-IP, proximity ligation, dsRBD mutants, S9.6 R-loop detection, ATR activation assays\",\n      \"pmids\": [\"37831098\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How R-loops outcompete TOPBP1 for ADAR1 binding not structurally defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Independently linked ADAR1-DHX9 interaction to R-loop suppression and ATR activation in cancer cells.\",\n      \"evidence\": \"Co-IP, R-loop detection, ATR assays, ADAR1 silencing, cell-cycle analysis in ovarian cancer cells\",\n      \"pmids\": [\"35711824\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative roles of editing vs binding in R-loop control not separated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established editing-independent control of Drosha stability linking ADAR1 to NF-κB-driven vascular inflammation.\",\n      \"evidence\": \"Co-IP of ADAR1-Drosha, macrophage-specific KO, aortic transplant, human AAA specimens, humanized model\",\n      \"pmids\": [\"36688311\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of ADAR1-induced Drosha degradation not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed editing-dependent miR-376b-3p seed retargeting alters GABA metabolism via ABAT.\",\n      \"evidence\": \"Editing analysis of miRNA precursors/mature forms, target validation, GABA and GABA-A receptor measurements\",\n      \"pmids\": [\"35124003\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological context of GABA-pathway regulation not established\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Resolved the direct, editing-independent mechanism of PKR inhibition: ADAR1 dsRBD3 contacts the PKR kinase domain on dsRNA, validated by structure-guided contact mutagenesis and triple-mutant rescue in vivo.\",\n      \"evidence\": \"Co-IP, editing-inactive and dsRBD3-PKR contact mutants, AlphaFold modeling, Adar;Mavs;Eifak2 triple-mutant mice\",\n      \"pmids\": [\"39146181\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structural detail of the inhibitory complex not crystallographically determined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Mapped distinct interactomes for nuclear p110 and cytoplasmic p150, showing dsRNA dependence and IFN-induced recruitment of p150 to antiviral stress granules.\",\n      \"evidence\": \"Endogenous and Strep-tag Co-IP, isoform-specific BioID, RNase A digestion, dsRNA-binding mutant\",\n      \"pmids\": [\"39673305\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of most isoform-specific partners not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Provided structural insight that dsRBD3 homodimerization tunes site-specific editing efficiency rather than global catalysis.\",\n      \"evidence\": \"Crystal structure of dsRBD3, interface mutagenesis, in vitro editing assays\",\n      \"pmids\": [\"39572551\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of dimerization-dependent site selectivity not demonstrated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed editing-independent suppression of ferroptosis via a miR-335-5p/Sp1/GPX4 axis in breast cancer.\",\n      \"evidence\": \"CRISPR KO and overexpression, miR-335-5p measurements, ROS/MDA/GSH/Fe2+ assays, GPX4 levels\",\n      \"pmids\": [\"38866351\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How ADAR1 controls miR-335-5p editing-independently not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified PACT as a cooperating suppressor of PKR alongside ADAR1, with synthetic lethality of combined loss rescued by PKR deletion.\",\n      \"evidence\": \"Genome-wide CRISPR-Cas9 FACS screen, ADAR1/PACT double KO, PKR KO rescue\",\n      \"pmids\": [\"40185749\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PACT and ADAR1 act on the same dsRNAs or independently not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ADAR1's many editing-independent activities (PKR/ZBP1 binding, Dicer/Drosha control, TOPBP1/R-loop functions, senescence and ferroptosis axes) are coordinated, isoform-partitioned, and prioritized within a cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model integrating editing-dependent and editing-independent roles\", \"Structural basis of most direct protein interactions undefined\", \"In vivo relevance of cancer-specific editing substrates versus immune functions unclear\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 1, 21, 28]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [1, 8, 14, 19]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [8, 16]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [8, 7, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [11, 19, 28]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [11, 19, 28]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 2, 3, 30]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [0, 27, 17]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [3, 4, 6, 7, 29]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [14, 26]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [12, 25]}\n    ],\n    \"complexes\": [\"Dicer-ADAR1 complex\", \"LINE-1 RNP\"],\n    \"partners\": [\"MDA5\", \"PKR\", \"ZBP1\", \"TOPBP1\", \"DHX9\", \"Drosha\", \"Dicer\", \"PACT\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}